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ABSTRACT
Characteristics and patterns of opioid-related overdoses among veterans
Sara C. Warfield
BACKGROUND AND OBJECTIVES: The United States is in the midst of an opioid overdose
crisis and is now considered a public health emergency. Given the alarming rise in opioid
overdose deaths, there is an urgent need to understand the characteristics and risks associated
with opioid overdoses. The objectives of this study were 1) to compare factors associated with
different type of opioid overdose, 2) to determine the conditional probability of repeat overdose
among veterans with a prior overdose event and corresponding probability of mortality for each
overdose event and, 3) to identify cause-specific mortality rate of those who experienced a
nonfatal overdose during our study period.
METHODS: Using clinical records and mortality files of more than 10.5 million veterans, we
extracted data among those with a documented opioid overdose between January 1, 2011 and
December 31, 2015. During this time, 13,333 veterans had at least one documented opioid
overdose of any intent.
RESULTS: Study 1. Patients who were younger in age (18-44 OR [odds ratio] 7.19, 45-64 OR
4.78) had significantly higher odds of a fatal index overdose and experiencing a repeat overdose
(18-44 OR 2.13, 45-64 OR 1.78). Having one or more chronic pain diagnoses was both
associated with experiencing a fatal index overdose (OR 3.96) or repeat overdose (OR 1.15). A
diagnosis associated with mental health or substance abuse or dependence was significantly
associated with experiencing a repeat overdose, (OR 1.54 and 1.25 respectively). Receipt of
medication-assisted therapy (MAT) more than one year prior (OR 1.28) to the first (i.e. index)
overdose was significantly associated with increased odds of a fatal overdose whereas receiving
counseling services prior to index overdose was protective of experiencing a fatal index
overdose. Study 2. One fifth of the study sample had a repeat overdose during the study period,
with a conditional probability that increased linearly for each subsequent overdose event. The
conditional probability of repeat overdose went from 21.1% on the second overdose to 43.2% for
five or more overdoses. Mortality was highest among the first documented overdose. Study 3.
Overall, veterans with a prior nonfatal overdose more often died from any cause in comparison
to their veteran peers and had approximately 26 times the mortality rate to the general U.S.
population. Veterans with a prior nonfatal overdose had a higher risk of death from substances
(aHR [adjusted Hazard Ratio] 5.0, 95% CI [confidence interval]: 4.4-5.8), including a higher risk
of death from drugs (aHR 6.9; 95% CI 5.8-8.1) and alcohol (aHR 2.7, 95% CI 2.1-3.6). For
cause-specific mortalities assessed between veterans in our cohort and the general U.S.
population, the standardized mortality rate ratio (SMR) was 114 times higher for deaths
associated with substances (95% CI: 98.8-128.7), 107 times higher for deaths associated with
hepatitis (95% CI: 65.5-152.7) and 68 times higher for deaths associated with liver cancers (95%
CI: 47.9-88.7). Overall, veterans in our overdose cohort had an elevated mortality rate than the
general public for all the specific causes of death assessed.
CONCLUSION: Although risk factors for opioid overdoses are well studied, there appears to be
differences between the type of opioid overdoses documented in a clinical setting. Given that
mortality is highest on the first documented overdose suggests that prevention efforts should be
further support to reach those patients at highest risk. Furthermore, given that the probability of

experiencing a repeat overdose increases with each overdose event suggest that healthcare
settings should be prepared to handle an influx in patients, specifically those with mental health
diagnoses. Moreover, given the elevated risk of death from all-causes, specifically those
associated with substances suggests the need for an integrated healthcare approach.
Understanding risks factors, type of overdose, and cause-specific mortality among patients with
an opioid overdose could help to inform healthcare interventions and potentially lead to better
patient outcomes.
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Chapter 1
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Chapter 1. Introduction
1.1 Background
Opioid overdoses have surged in the past decade and deaths from overdose are now considered
one of our country’s most serious public health crises. Between 2007 and 2017 there were more
than 507,000 overdose deaths in the United States; with more than half of these involving
opioids [1-4]. Concurrent with the rise in overdose deaths, hospitalizations related to opioid
abuse and misuse have also been on the rise [5, 6]. Between 2009 and 2014, opioid overdoses
resulting in inpatient hospital admission increased more than 60%, emergency department visits
nearly doubled [5] and costs associated with overdose morbidity and mortality have been
estimated to exceed $22 billion annually [7, 8].
Despite the impact associated with opioid overdose on the healthcare system, few studies have
examined information available from electronic health records in conjunction with vital records
to examine risk for opioid overdose or to inform prevention and clinical programs. There are a
number of unanswered questions related to the combinations of medical diagnoses and social
conditions as potential risk factors for overdose, particularly among populations with evidence of
abuse or misuse. To date, there have been a limited number of studies that examined the etiology
of repeated opioid overdoses or compared them with characteristics associated with fatal
overdose. [9-11]. Similarly, little is known about the patterns of cause-specific mortality risk
among those with history of at least one nonfatal overdose [12, 13]. Understanding risk factors
for repeated overdose and mortality following a nonfatal overdose could inform healthcare
interventions and in turn, better patient outcomes.
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1.1.1 Risk Factors for Overdose
Individual-level risk factors for opioid overdose include sex (male), age (particularly 18 to 45
years), race/ethnicity (non-Hispanic white), and residence in a rural area; particularly the
Appalachian region [2, 3, 14-18]. Physical health conditions associated with an increased risk of
overdose include diagnoses associated with chronic pain, liver disease, renal disease, chronic
pulmonary disease, cardiovascular disease, musculoskeletal injury, cancer, and skin and softtissue infections [19-22]. Mental health diagnoses and related factors associated with overdose
risk include depression, anxiety , history of suicide attempt or ideation, post-traumatic stress
disorder (PTSD), bipolar disorder, attention deficit disorder (ADD), frequent or severe
psychological distress, and substance use disorder (SUD) [19-21, 23-27]. While many risk
factors for overdoses have been previously studied, they have largely examined risk factors
among people who inject drugs (PWID) or individuals taking prescription opioids; primarily due
to chronic non-cancer pain [17, 22, 26, 28-32]. Moreover, a majority of studies have focused on
identifying risk factors using information obtained from cross-sectional surveys. Risk factors
associated with opioid overdose are detailed in Table 1.
1.1.2 Epidemiology of Overdose and Veterans Who Use VHA Services
Evidence suggests that risk factors associated with opioid overdose among veterans who have
utilized Veterans Health Administration (VHA) services are similar to those identified among the
general U.S. population. Risk factors assessed in previous studies include dosage of prescribed
opioids, duration of prescribed opioids [20, 22, 25, 33] , medical conditions associated with
chronic pain, and diagnoses or symptoms associated with psychiatric disorders [25, 34, 35].
Although risk factors for overdose are similar to those in the general population, research
suggests that more veterans who use VHA services have history of some risk factors associated
3

with overdose morbidity and mortality, such as chronic pain and mental health diagnoses, which
in turn may be associated with higher overdose mortality rate among members of this population
[24, 36, 37]. Further, previous research among veterans found that over 60% of patients who
experienced an unintentional opioid overdose were seen in an outpatient setting in the month
prior to their overdose and approximately 30% of those were for mental health treatment [38,
39]. While many risk factors for fatal overdose have been previously identified, existing studies
largely examined unintentional overdose death or risk factors for overdose among those with
access to prescription opioid pain relievers; primarily due to chronic pain [18, 20, 22, 25, 29, 35,
40, 41]. Although medical diagnoses capture a variety of risk factors associated with overdose
mortality, they do not capture all potential risk factors or information available from electronic
medical records. Environmental and social stressors have been previously identified as risk
factors for substance abuse, yet little is understood about the unique contribution of these factors
or the combined influence of environmental and social stressors and medical/psychiatric
diagnoses.
Numerous studies have found that social determinants of health (SDoH) are often significantly
associated with negative outcomes [42-44]. SDoH that are the most significant for health
outcomes are often those associated with socioeconomic status, such as economic instability or
inadequate housing [42, 45]. Factors such as homelessness and early life adversity, have also
been shown to influence risk for drug use and mental health disorders [46, 47]. Indicators of
social determinants of health can be assessed in electronic health records (EHR) through certain
V codes (ICD-9) and Z codes (ICD-10). Although these social codes can be used in any
healthcare setting, studies have shown they are generally underutilized by most healthcare
professionals other than mental health professionals [44, 48].
4

Looking beyond the primary and secondary diagnostic codes may provide an opportunity to
describe the social, behavioral, and environmental factors, also known as contextual factors,
which may be associated with overdose risk [48-52]. Such findings could inform additional
strategies designed to reduce overdose deaths attributed to opioids. Although studies have
examined outpatient visits prior to an overdose, no existing study has examined contextual
factors prior to an overdose and few have identified these factors in conjunction with health
diagnosis in the veteran population [38, 39].
It is possible that previously identified risk factors may be exaggerated among veteran
populations, such as mental health diagnoses (i.e. post-traumatic stress disorder (PTSD) or
chronic pain [24, 25, 33, 34, 53]. Studies conducted using data from VHA records have
consistently found that veterans have a high rate of mental health diagnoses, including substance
use disorder (SUD),[20, 34, 53-55]; a potentially important risk factor to overdose morbidity and
mortality[20, 24, 25, 36].
1.1.3 VHA and Electronic Health Records
Data from EHRs can be used in addition to mortality and prescribing surveillance systems to
monitor trends as well as identify clinical characteristics associated with a myriad of health
outcomes in a timely manner. EHRs hold a comprehensive list of healthcare factors such as
diagnosis codes, procedure codes and medication data, allowing for a deeper understanding of
various health outcomes. Linking clinical and death records together can leverage data between
these two sources to enhance the understanding of corresponding risk for health outcomes.
Findings from rich data sources like EHRs can inform future healthcare efforts targeting patients
at risk for overdose.
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Given the growing concern for opioid overdoses across the U.S., there is a need to enhance
information used to understand risk for and prevention of overdose morbidity and mortality.
Further, the majority of risk factors identified have focused on single episodes (either fatal or
nonfatal) and comparatively little is known regarding the risk factors for repeated overdose.
1.1.4 VHA population
The VHA is one of the largest integrated healthcare system in the United States and collects data
on clinical diagnosis, procedures, medications, and sociodemographic information from more
than six million patients annually. Currently, the largest proportion of veterans receiving VHA
medical care served in the Vietnam Era [56].
Serving more than six million patients annually, the VHA provides an array of comprehensive
healthcare services for a myriad of health conditions. VHA services are provided in 170 medical
centers and 1,243 outpatient clinics throughout the U.S. [56]. Available data suggests that
patients seeking care from the VHA often have poorer health outcomes, such as chronic pain and
psychiatric comorbidities, and multi-system diagnoses, which could increase risk of negative
health outcomes [57, 58]. In 2003, it was estimated that more than one million veterans who use
VHA services have been diagnosed with either a substance abuse disorder or other mental health
condition [59]. Accordingly, mental health and substance use disorders are considered a
significant issue among the veteran population [60, 61]. Previous research suggests that more
than 55,000 veterans who use VHA services have been diagnosed with an opioid use disorder
(OUD)[62]. The breadth of data collected by the VHA coupled with the evidence of elevated risk
factors among the patient population provides a unique opportunity to use information from this
health care system to identify previously unexplored risk factors and targeted strategies to reduce
opioid-related morbidity and mortality.
6

1.1.5 Current Prevention Efforts
Primary prevention strategies for opioid abuse and overdose prevention have largely focused on
reducing the excess supply of prescription opioids, including the development and support of
safe prescribing guidelines and the implementation of prescription drug monitoring programs
(PDMP). Secondary and tertiary efforts have been primarily focused on addressing the gap in
treatment and distribution of naloxone, a rapid acting opioid antagonist [63-65]. Importantly,
one consequence of the increased distribution and resulting availability of naloxone is the
associated increase in probability of surviving an overdose and related history of multiple
overdoses.
In recent years, the VHA has amplified efforts to reduce risk of opioid overdose among patients
receiving care from clinicians in its facilities. In an effort to promote safer prescribing the VHA
introduced the Opioid Safety Initiative (OSI) which leverages prescription data within the VHA
and helps clinicians identify patients at risk for adverse risks from opioids. In addition to the
OSI, the VHA developed a dashboard to identify patients at risk for an adverse event related to
opioids [63, 66]. Furthermore, the VHA has developed academic detailing on opioid abuse and
overdose prevention in an effort to provide health care professionals with evidence-based
educational tools [66]. To further reduce the burden of opioid overdose among veterans, the U.S.
Department of Veterans Affairs also developed the Opioid Overdose Education and Naloxone
Distribution (OEND) program. This program primarily focuses on educating health care
professionals and high-risk patients on strategies to prevent, identify, and reverse an opioid
overdose. Veterans with a history of injection drug use, substance use such as heroin, a diagnosis
of opioid use disorder (OUD), or those with a high likelihood of opioid overdose or witnessing
an overdose are targeted for the OEND program. These patients’ are often identified in medical
7

settings including but not limited to treatment programs such as Medication-Assisted Treatment
(MAT), inpatient withdrawal management, syringe access programs, emergency departments,
homeless shelters and other primary health care settings[67].
1.2 Purpose Statement
Given increases in overdose deaths, there is a need to identify opportunities for intervention and
prevention services informed by a better understanding of risk for repeat overdose and mortality.
The primary aim of this study is to identify and assess the risk factors such as demographic
characteristics, medical diagnoses and indicators of social determinants of health associated with
risk for repeat overdose and all-cause mortality among patients with a history of one opioid
overdose.
The proposed project seeks to expand upon existing efforts using data from VHA administrative
records to inform strategies for clinical interventions and preventive services targeting veteran
groups at increased risk for a fatal opioid overdose or repeat opioid overdose.
Results from this project will specifically add to the literature in the following ways:
1.

Increase understanding of potential differences in risk for nonfatal, repeated and fatal
overdose.

2. Calculate associations between an increasing number of nonfatal overdoses and risk for
mortality or repeated events.
3. Assess all-cause and cause-specific mortality risk among veterans with a documented
opioid overdose.
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1.3. Specific Aims
Sample design
Veterans with a documented opioid-related overdose were identified using clinical and
administrative records from the Veterans Health Administration (VHA) Corporate Data
Warehouse (CDW) and the VA/DoD Suicide (all-cause) Data Repository (SDR) respectively.
The process flow of data into the CDW is shown in Figure 1 and specific ICD-9 and ICD-10
codes used for the opioid overdose is in Appendix A and corresponding variables of interest are
listed in Appendix B (demographic and diagnostic variables), C (codes which serve as indicators
of social determinants of health) and D (codes used to define cause-specific mortality).
Underlying cause of death codes used to identify cause-specific mortality can be found in
Appendix D.
We identified all veterans who utilized VHA services between calendar years 2011 through 2015
by accessing patient information available from VHA’s administrative and EMR data files.
Social Security Numbers (SSNs) were used to link to the CDW and SDR records. We extracted
potential predictor variables including demographic information such as sex and age, procedural
codes and diagnostic codes for the study period (2011-2015). An additional year of data was
extracted if the index overdose occurred in the first year of the study period. For instance, if an
individual had an opioid overdose (nonfatal or fatal) in January 2011, procedural and diagnosis
codes were pulled from one year prior (January 2010) to index overdose.
Inclusion/Exclusion criteria
The cohort was restricted to veterans over 18 years or under 90 years. We excluded patients that
did not have a follow-up visit within one year of a non-fatal overdose event. Patients with a death
9

date prior to an overdose diagnosis date were also excluded from analysis (n=145, 0.89%). Given
that repeated overdose occurred on average more than one month after the index overdose
(mean=36 days), patients were excluded if the first nonfatal overdose occurred in the last three
months of the study period (October 1, 2015 to December 31, 2015). This mitigated potential
bias among those with less than three months of documented time at risk following an overdose
event.
Opioid overdose cohort
A nonfatal opioid overdose was identified using International Classification of Disease, Ninth
Edition (ICD-9) 965.00-965.02, 965.09, E850.0-E850.2. Similarly, ICD Tenth Edition (ICD-10)
codes were used to identify opioid overdose: X40-X44, X60-X64, X85, and Y10-Y14 and
secondary-axis codes T40.0- T40.4, and T40.6 (Appendix A). The first opioid overdose
documented in the compiled records was coded as the index overdose. Multiple opioid overdoses
that occurred during an inpatient treatment stay were counted as a single overdose event, based
on admission and discharge date. Repeat overdoses were identified among veterans with more
than one opioid overdose recorded during the study period. A repeat overdose was defined as a
second documented overdose that occurred a) two days after the index event with principal
diagnosis of an overdose or b) 3 days or more after a prior overdose. Any record of an overdose
within one day of a previous overdose was treated as the same event.
We identified 13,333 patients with a record of an opioid overdose between the calendar years
2011 through 2015. Of those, there were 4,949 (37.1%) opioid overdose deaths, with a majority
occurring on the first documented overdose (n=4,890, 98.8%). Furthermore, among these
overdose deaths, 85.0% were unintentional (n=4,206), 6.4% were undetermined (n=315), 8.5%
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were intentional (n=422) and 0.1% were homicide (n=6). Figure 2 depicts the specific inclusion
and exclusion criteria for each of the specific aims.
Predictors
Demographic characteristics were extracted using clinical and administrative rules set by the
VHA. For instance, sex was based on last entered value for analysis. Age was static and based on
the patient’s age on the start of the study period, January 1, 2011.
Date of diagnosis was based on the day of visit for the outpatient population or the date of
discharge for the inpatient records. Potential predictors were examined one year prior to first
documented overdose and at any point during the study period.
All predictors were dummy coded and additional variables were created based on time of
diagnosis, particularly in relation to index overdose. This helped describe the potential
relationship between diagnosis and type of overdose experienced.
This study was reviewed and approved by the Institutional Review Board at the Syracuse VA
Medical Center, New York.
Analysis plan
For all aims, data management and analysis were conducted using SAS Enterprise Grid software
(version 5.1, SAS Institute Inc.). Descriptive analysis for all variables were completed using
cross tabulations, column percentages were reported for each outcome of interest. Alpha was set
to 0.05 for tests unless otherwise specified.
Specific Aim 1: Characterize differences between those with a fatal index overdose and
those with repeated nonfatal overdoses from those with only one nonfatal index overdose.
11

Based on results from existing studies, we hypothesize that those who experienced repeated
overdoses would have a greater number of psychiatric diagnoses and social health indicators
than those who died on their first documented overdose [24, 68-71].
Bivariate analyses were conducted using chi-square test of difference among all
sociodemographic and diagnostic variables by overdose category: fatal index overdose, repeated
nonfatal overdoses, and only one nonfatal overdose. The primary hypotheses was tested using
multinomial logistic regression given the polytomous outcome includes three mutually exclusive
groups without order. As an extension of logistic regression models, this approach is flexible and
allowed three overdose outcome levels using a generalized logit link. In addition, this approach
provided a more direct option for interpreting the relationship between the predictors and
outcome groups [72], is more robust to violating the assumptions of normality and does not
assume a linear relationship between the predictors and outcome [72, 73]. Conversely, this
method required additional comparative statements given that this method produced multiple
odds ratios for each predictor; which could lead to issues with interpretability [72, 74]. A major
limitation of this method may result from the independence of irrelevant alternatives (IIA)
assumption which presumes that changing the number of outcomes (e.g. three to five levels)
would not affect the odds of the remaining outcomes [75, 76]. Model fit for this multinomial
logistic regression model was first assessed by using a series of logistic regression models,
controlling for age and gender, which is known to influence overdose risk[74, 77]. Assumptions
for multinomial logistic regression models were tested. For example, multicollinearity was
assessed by calculating variance inflation factors (VIF). Predictors with a VIF greater than 10
were reassessed for strength of relationship with the outcome. Of those predictors where
collinearity was suspected, Wald chi-square tests were conducted to determine which variable
12

was more appropriate for inclusion in the final models. Weaker predictors were dropped and the
model was rerun to only include significant predictors that were not collinear. Goodness of fit
indices such as the Type 3 Analysis of Effects and Wald chi-square test were examined for all
predictors with the null that all of the coefficients were equal to zero in the model[72].
Interactions between significant predictor variables were tested and significant interactions were
left in the model. Odds ratios with a 95% Confidence Interval (CI) were calculated by
exponentiating the estimate. The adjusted odds ratio indicate the odds of experiencing a fatal
overdose compared to those with one nonfatal overdose as well as the odds of experiencing a
repeated nonfatal overdose compared to those with one nonfatal overdose, adjusted for all other
predictors in the model.
Specific Aim 2: Calculate the conditional probability of a repeat opioid overdose event
(fatal and nonfatal) among those with record of a nonfatal opioid overdose. We expect that
the conditional probability for repeated overdose and mortality will increase linearly with each
overdose event.
The frequency and conditional probability of nonfatal and fatal overdose was calculated among
the VHA patient population with at least one overdose event during the study period (20112015). We excluded overdoses that were classified as homicides or suicides. To describe the
magnitude of repeated overdose and corresponding mortality for each overdose event, the
conditional probability of repeated overdose and associated mortality was calculated for patients
with at least one documented overdose in the VHA clinical records. Conditional probability of
an overdose was calculated by dividing the proportion of patients experiencing the event by the
number of patients at risk for the event [78-80]. The outcome of interest was mortality at each
overdose event (e.g., one, two, three, four, and five or more overdoses) as well as conditional
13

probability for repeated overdose event. Conditional probabilities for overdose death and repeat
overdose at each disease event were estimated and 95% CI were extrapolated using the normal
approximation method.
Specific Aim 3: Determine the 5-year cause-specific mortality rate of those who experienced
a nonfatal opioid overdose. We hypothesize that the mortality rate will be markedly higher
among veterans with a prior nonfatal overdose. Further, we hypothesize that select categories of
mortality, including suicide and substance-related mortality, will be significantly higher among
patients with one or more previously documented overdose events.
The number of person-years at risk of dying and relative frequencies of overall and causespecific causes of death were compared between those who experienced a nonfatal opioid
overdose and a control group. Those who died from a fatal index overdose were excluded from
the analysis. We also excluded those with a nonfatal overdose in the last three months of the
study period. We evaluated vital status for the nonfatal overdose group and comparison group
from the start of the study period, January 1, 2011. Continuous variables were examined to
determine overall distribution and bivariate analysis was used to examine bivariate relationships.
A 5% stratified random sample was pulled to compare mortality with the nonfatal overdose
group. Pulling a stratified random sample allowed the control group to be similar in composition
to those with a nonfatal overdose [81]. Given that VHA users are commonly older male with
poorer health outcomes, we stratified by sex and age to reduce potential bias that may influence
mortality among the control group [56, 58]. This method, using a stratified random sample, has
been used in previous VHA research using clinical data due to the large sample size of the
population [82-85]. This method allowed for controls to be pulled from a heterogeneous
population based on specific strata, specifically sex and age [86-88]. The control group was
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constructed to compare differences in mortality between those who experience a nonfatal opioid
overdose to those with no documented overdose and allowed for outcome measures to be easily
extrapolated for each stratum. We hypothesized that the mortality rate would be markedly higher
among the nonfatal overdose group in comparison to the control group, given previous mortality
research among a clinical population with a prior nonfatal overdose[12]/
We evaluated mortality from the start of the study period (January 1, 2011) through the end of
the study period (December 31, 2015). Follow-up for the study ended the day the patient died or
the end of the study period, whichever occurred first. In addition to all-cause mortality, causespecific mortality was extrapolated for the following categories: external causes of death,
suicide, homicide, accidents, substance-related deaths, drug-related deaths, alcohol-related
deaths, infectious, viral hepatitis, human immunodeficiency virus (HIV), circulatory system,
respiratory system, influenza, chronic respiratory disease, digestive system, cirrhosis and
alcoholic liver disease and cancers. Specific types of cancers were categorized into the following
groups using the International Classification of Diseases for Oncology [89]: lung and bronchus,
liver and intrahepatic bile duct, digestive system cancers, which included esophageal, stomach,
small intestine, colon, rectal, anal, gallbladder and pancreatic cancers, lymphoma and leukemia
and other cancers. (See Appendix D for the full list of cause-specific mortality and
corresponding ICD-10 codes).
To test study hypotheses, cox proportional hazard models were used to calculate relative risk
estimates and included demographic factors (e.g. sex and age) as covariates. Using this type of
analysis we assumed the following: 1) the hazard ratio remained constant over time, 2) the
independence of survival was different between each veteran in the cohort and 3) there was a
multiplicative relationship between the predictors [90]. This semi-parametric method has been
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used in similar research to elucidate the relationship between multiple predictors and mortality
[12, 83, 91]. We assessed the proportional hazard assumption by comparing the observed with
the predicted survival curves for categories of the variables in the model, curves that were
relatively close indicated the hazard ratio remained constant over time [92]. Significant
predictors were identified using Wald Z-tests which evaluated whether hazard ratio was equal to
one or equivalently that the slope was equal to zero [92]. Given that a cox proportional hazard
model is a likelihood-based method, the overall model fit was evaluated through likelihood ratio
(LR) tests. Given the large sample size of the cohort, results from the LR test were close to Wald
test. Interactions between two different variables were assessed to determine significance by
examining Akaike information criteria (AIC) levels in comparison to the model without
interaction terms. We detected violations of the hazard assumption by examining the Schoenfeld
residuals [93]. Hazard ratios and corresponding 95% CI were extrapolated for cause-specific
mortality.
We identified person-years of follow-up and mortality rates per 10,000 person-years for the
cohort. Crude death rates were calculated and adjusted mortality rates were calculated using Cox
proportional hazard models, adjusting for age and sex.
Mortality rates among veterans with a nonfatal overdose were compared to mortality rates in the
US population. Standardized mortality rate ratios (SMRs) were calculated using data from the
Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic
Research (CDC WONDER). In order to obtain approximate estimates, age-adjusted mortality
rates were pull for the cause specific deaths of interest among individuals between 15 and 84
years using data from CDC WONDER. SMRs were calculated for specific causes of death by
dividing the observed number of deaths to the expected deaths [94, 95].
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Limitations
Although the VHA is the largest healthcare system in the United States, a major limitation of this
study is that it only examines individuals who access healthcare through the VHA. Moreover,
these study results may not generalize to the US population given the homogeneity of the veteran
population. Moreover, veterans using VHA healthcare often experience a number of physical and
mental health conditions compared to the general population which could result in a higher
number of comorbidities or utilization of health care services [57]. These estimates may suffer
from Berksonian bias, which appears when the sample is different than the general population
leading to biased findings and is common among studies that use electronic health records [95].
However, the use of comparison groups and controlling for potential confounding will reduce
potential bias that may occur. In addition, health services could be utilized outside of the VHA
which could alter findings, showing a lower utilization of actual health care services. The CDW
only captures overdoses documented in the VHA system which may lead to an underestimate on
the true number of overdoses. Another potential limitation could occur when linking datasets
(CDW and SDR) resulting in missed overdose deaths resulting in an underestimate of total
deaths. However, records were required to match fully on SSN and 80-90% based of the
additional characteristics including name, date of birth and sex.
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Table 1. Risk factors for opioid overdose
Population characteristics
Demographics
♦

Male

♦

Ages 18-45

♦

Non-Hispanic white

♦

Rural

♦

Appalachian region

Physical health conditions
♦

Chronic pain

♦

Liver disease

♦

Renal disease

♦

Chronic pulmonary disease

♦

Cardiovascular disease

♦

Traumatic injury

♦

Cancer

♦

Soft skin and tissue infections

Mental health conditions
♦

Mental distress

♦

Depression

♦

Anxiety

♦

Previous suicide attempt

♦

PTSD

♦

Bipolar disorder

Substance Use
♦

Substance Use Disorder (SUD)


History of opioid dependence or abuse
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♦

♦

Drug use(opioids, specifically heroin)


High MME/day (e.g. more than 90 MME/day)



Severity of substance use

Co-prescribed opioids with benzodiazepines, antidepressants or antipsychotics
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Figure 1. Process Flow of CDW

Abbreviations: CDW, Corporate Data Warehouse; VHA, Veterans Health Administration
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Figure 2. Sample Design for the Opioid Overdose Cohort

Abbreviations: CDW, Corporate Data Warehouse; SDR, Suicide Data Repository
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2.1 Abstract
Objective
To compare demographic and diagnostic criteria associated with different categories of opioid
overdoses including: fatal index (i.e. first recorded), single nonfatal, and repeat overdose
(nonfatal).
Methods
Electronic health records (EHR) from the Veterans Health Administration (VHA) and death
records from the Department of Veterans Affairs (VA)/Department of Defense (DoD) Joint
Suicide (all-cause) Data Repository (SDR) were used to identify veterans with at least one
documented opioid overdose between 2011 and 2015. Bivariate analyses were used to describe
opioid overdose category and associated variables including sociodemographic characteristics,
diagnostic factors such as chronic pain, mental health diagnosis, prior substance use, and codes
associated with social determinants of health. Multinomial logistic regression was used to assess
factors associated with fatal index overdose versus repeat overdose and one nonfatal overdose.
Results
A total of 12,848 VHA patients had at least one opioid overdose documented in VHA’s EHR
between 2011 and 2015. Among them, 34.7% (n=4,464) died on their first documented overdose,
20.7% (n=2,659) had at least one additional (i.e. repeat) documented overdose, and 44.6%
(n=5,725) had only one nonfatal overdose in their medical records. Patients who were younger in
age (18-44 OR [odds ratio] 7.19, 45-64 OR 4.78) had significantly higher odds of a fatal index
overdose and experiencing a repeat overdose (18-44 OR 2.13, 45-64 OR 1.78). Having one or
more chronic pain diagnoses was associated with experiencing a fatal index overdose (OR 3.96)
29

or repeat overdose (OR 1.15). A mental health or substance abuse or dependence diagnosis was
significantly associated with experiencing a repeat overdose, (OR 1.54 and 1.25 respectively).
Receipt of medication-assisted therapy (MAT) more than one year prior (OR 1.28) to the first
(i.e. index) overdose was significantly associated with increased odds of a fatal overdose
whereas receiving counseling services prior to index overdose was protective of experiencing a
fatal index overdose.
Conclusion
To reduce overdose mortality and repeat morbidity, prevention efforts should target younger to
middle aged veterans, especially those with a chronic pain diagnosis. Healthcare efforts should
focus on treating mental health diagnoses, which are significantly associated with multiple
overdoses. Healthcare efforts should consider integrating relapse prevention in primary care
settings, to mitigate potential risk among patients with a history of an overdose.
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2.2 Introduction
Overdoses are now the leading cause of accidental death in the United States and are a growing
concern for public health and clinical medicine. Fatal opioid overdoses have been on the rise
since 1999 and have more than quadrupled in the United States during this time period [1-6]. In a
similar fashion, nonfatal overdoses have also been increasing. Fatal and nonfatal overdoses are
highest among people who inject drugs (PWID) [7-9], have an opioid use disorder (OUD) [10,
11], or consume a high-dose of opioids [12-17].
Prior research has found that risk factors for nonfatal overdose [13, 18-28] are similar in nature
to those for fatal overdose [15, 17, 29-32]. The most significant risk factors for overdose include
those related to mental health such as a diagnosis of anxiety, depression, or a history of suicide
ideation or attempt [7, 22, 23, 28, 33-35]. Diagnostic risk factors such as chronic pain,
respiratory disease, renal disease, and cardiovascular disease have also been associated with
overdose risk but were not as strong as those associated with mental health diagnoses [22, 23, 33,
34]. Research conducted among PWID suggest that homelessness and early life adversity are
also associated with increased risk for substance abuse and overdose [30, 36, 37]. While studies
have identified social determinants of health as significant risk factors of overdose, no studies
have used EHRs to assess differences across categories of overdoses.
Existing evidence suggests that the number of prior overdoses is directly related to subsequent
risk of death from overdose[38]. Furthermore, research suggests there has been a rise in patients
hospitalized for repeat overdose events. However, little is known about risk factors for repeat
overdose or if they may differ from those identified with increased risk of overdose mortality
[39]. The few studies that have examined repeat overdoses have examined intentional overdoses
rather than those that were thought to be unintentional or of undetermined intent [40-43].
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The purpose of this study was to identify diagnostic factors, including codes related to social
determinants of health, associated with different opioid overdose categories including fatal index
overdose, a single nonfatal overdose, and repeat overdose (nonfatal) using data from the one of
the largest integrated health care systems in the U.S.
2.3 Methods
Study population
We pulled a cohort of veterans who received services from the Veteran Health Administration
(VHA) in calendar years 2011-2015. Opioid overdoses were extracted using clinical records
from the VHA Corporate Data Warehouse (CDW) linked with death records from the VA/DoD
Suicide Data Repository using Social Security Numbers (SSNs) [44-47]. To allow for time to
risk, patients were excluded if their first overdose occurred in the last three months of the study
(October 1, 2015 through December 31, 2015). Patients were also excluded from the study or if
they did not have follow-up records within the year following a nonfatal overdose. This study
was restricted to veterans over 18 and under 90 years of age. This cohort identified 13,333
veterans with at least one documented opioid overdose between 2011 through 2015. After
excluding those who died from overdoses classified as suicide (n=422) or homicide (n=6), or
those that died on a repeat overdose (n=57), the final study cohort was 12,848.
Opioid overdose
Opioid overdose was defined using International Classification of Disease, Ninth Edition (ICD9) codes: 965.00-965.02, 965.09, E850.0-E850.2 and ICD Tenth Edition (ICD-10) codes: X40X44, Y10-Y14 and secondary axis codes T40.0- T40.4, and T40.6. Repeat overdose was defined
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as either a) a second documented overdose that occurred two days after the previous overdose,
with the overdose documented as the principal diagnosis or b) a second documented overdose
that occurred three days or more after the previous overdose. An overdose that occurred one day
after a prior overdose was treated as the same event. The outcome of interest was category of
opioid overdose: including categories for fatal index overdose, repeated nonfatal overdoses, and
only one nonfatal overdose, which were constructed as three mutually exclusive groups.
Predictors
We extracted information on six domains of predictors for veterans receiving medical care from
the VHA [46, 48]. These domains included demographic, chronic pain, mental health, substance
abuse/dependence, MAT, and social codes, which serve as indicators of social determinants of
health. Demographic information included age and sex of the patient. Information on race and
ethnicity were not included due to limited availability and documented lack of reliability [49,
50]. Age was fixed and determined based on age on the first day of the study period (January 1,
2011). Sex was determined based on last entered value for sex in either the clinical or death
records.
Chronic pain
Chronic pain diagnoses were categorized into seven diagnostic groups: arthritis, back pain,
migraines, headaches or tension headaches, psychogenic pain, neuropathy, and fibromyalgia. If a
patient had a diagnosis of at least one chronic pain diagnosis, a dummy variable was created to
identify the association between any chronic pain diagnosis prior to index overdose and type of
subsequent overdose (i.e. any chronic pain diagnosis prior to index overdose). Classifications for
chronic pain were guided by previous research [51].
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Mental health
A broad definition of mental health diagnosis was identified using ICD-9 codes 290.00 to 319.99
or ICD-10 codes F00 to F99, excluding tobacco codes starting with 305 or F17 [52, 53]. Eight
specific types of mental health disorders were categorized and included anxiety, depression,
bipolar, PTSD, adjustment disorder, schizophrenia or other psychotic disorders, traumatic stress,
and personality disorder. Two combination variables were then created to identify potential
interactions between types of mental health diagnoses and included: 1) having either depression,
anxiety, or PTSD, and 2) having all three mental health diagnoses (i.e. depression, anxiety, and
PTSD). Similar to chronic pain diagnoses, a dummy variable indicating any mental health
disorder was used to assess the relationship between mental health diagnoses and type of
documented overdose.
Substance abuse or dependence
Substance abuse or dependence was measured using seven types of substance abuse or
dependency groups including alcohol, opioid, cannabis, sedative, hypnotic, or anxiolytic,
cocaine, other stimulant, and hallucinogens. Similar to chronic pain and mental health diagnoses,
patients with any type of substance abuse or dependence documented in the clinical record were
then categorized as having any type of substance abuse or dependence. Patients with more than
one type of substance abuse or dependence were also identified as having polysubstance abuse or
dependence to assess the potential relationship between substance abuse/dependence for multiple
substances and type of overdose. Due to limited numbers, three types of substance
abuse/dependency disorders were not included in tables but were included in the composite
variable identifying any substance abuse/dependence or polysubstance abuse/dependence. Type
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of substances explored but not specifically retained in tables include the three categories:
cannabis, hallucinogens, and sedative, hypnotic, or anxiolytic substances.
MAT
Receiving MAT services was identified by a documented primary or secondary stop code 523,
which identifies buprenorphine or methadone treatment in the clinical record [54-56]. Patients
who received MAT prior to their index overdose were then further identified as having MAT
more than one year prior to overdose. Exploratory analyses identified more than one year as a
critical time point for last MAT rather than one, three or six months prior to index overdose.
Social determinants of health
Codes that are indicators of social determinants of health were collapsed into the following 13
categories guided by previous literature (Torres et al., 2017; Gottlieb et al., 2016): 1) problems
related to employment or unemployment, 2) problems related to education and literacy, 3)
problems related to housing or economic circumstances, 4) problems related to mental or
behavioral health, 5) problems related to upbringing, 6) problems related to social environment,
7) problems related to primary support group, 8) problems related to psychosocial circumstances,
9) problems related to environmental psychosocial circumstances, 10) problems related to abuse,
11) problems related to lifestyle or lifestyle management, 12) receipt of counseling services, and
13) receipt of counseling services for substance abuse.
The specific diagnostic codes (ICD-9 and ICD-10) used for the predictor variables can be found
in a Supplemental Table 1.
This study was reviewed and approved by the Institutional Review Board at the Syracuse VA
Medical Center, New York.
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Analysis
Data for this study was analyzed using SAS Enterprise Grid software (version 5.1, SAS Institute
Inc.). Descriptive analysis for all potential predictors were completed using cross tabulations for
all outcomes and alpha was set to 0.05 for tests unless otherwise specified.
Bivariate analyses were conducted using chi-square test of difference, for all predictor variables
with each overdose outcome: fatal index overdose and repeated nonfatal overdoses (Table 1).
The reference group for all analyses was a single nonfatal opioid overdose.
Using multinomial logistic regression, the odds ratios for repeat overdose and fatal index
overdose were calculated for sociodemographic and diagnostic factors such as chronic pain,
mental health diagnosis, prior substance use, and codes associated with social determinants of
health. Multinomial regression was used to provide a more direct interpretation for the
relationship between the predictors and category of overdose [57, 58]. As an extension of logistic
regression, this method was selected because it is more robust to violating assumptions of
normality and ability to compare across multiple outcome groups(57, 58). Model fit for this
multinomial logistic regression model was assessed by using a series of logistic regression
models, controlling for age and gender [59, 60]. Assumptions for this method were testing by
assessing multicollinearity among predictors with a variance inflation factor (VIF) with a critical
value greater than ten. If evidence of collinearity was identified among predictors, Wald chisquare tests were conducted to determine which variable was best suited for inclusion in the final
model. Goodness of fit indices such as the Type 3 Analysis of Effects and Wald chi-square test
were examined for all predictors [61]. Interactions between significant predictor variables were
tested.
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Adjusted odds ratios (OR) with 95% Confidence Intervals (CIs) were calculated for each of the
significant predictors in the final model (Table 2). Adjusted odds ratios indicate the odds of
experiencing a fatal overdose compared to those with one nonfatal overdose as well as the odds
of experiencing a repeated nonfatal overdose compared to those with one nonfatal overdose,
adjusted for all other predictors in the model.
2.4 Results
Our cohort consisted of 12,848 veterans with at least one documented overdose between calendar
years 2011 to 2015. This retrospective cohort consisted primarily of men (91.5%, n=11,070)
between the ages of 45-64 (61.3%, n=7,874). More than half had at least one chronic pain
diagnosis (69.6%, n=8,941) the most common types of chronic pain among our cohort was
arthritis (55.5%, n=7,129) and back pain (50.8%, n=6,521). Among our study cohort more than
90% had a mental health diagnosis during the study period (91.6%, n=11,768). The most
common mental health diagnoses were depression (75.5%, n=9,703) followed by anxiety
(60.8%, n=7,807), and PTSD (47.8%, n=6,146). In fact, 84.9% (n=10,906) of our cohort had at
least one of those mental health diagnoses and 32.8% (n=4,208) had record of all three. A
majority of the cohort (64.6%, n= 8,303) had at least one diagnosis associated with substance
abuse or dependence and 40.5% (n=5,203) had more than one substance abuse or dependence
diagnosis. Among our entire cohort, 11.1% (n=1,424) received MAT during the study period and
among those 76.1% (n=1,084) had MAT before their index overdose. Of those who received
MAT prior to their index overdose, 64.9% (n=704) last received MAT more than one year before
the first overdose recorded in their VHA medical record.
Diagnostic codes that are known as indicators of social determinants of health, or social codes,
were present in the EHR for 92.4% of our cohort (n=11,867). The most common social code
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documented for this cohort was receipt of counseling services, with 88.3% (n=11,338) having at
least one counseling code on record prior to their index overdose. The other social codes which
were frequent among this cohort were those indicating problems with housing or economic
circumstances (39.6%, n=5,082) and problems associated with psychosocial circumstances
(44.7%, n=5,739). (Table 1)
Bivariate analyses showed notable differences in group compositions between those who died on
their first overdose, those with repeat nonfatal overdoses, and those with only one nonfatal
overdose (Table 2). There were significant differences in the age distribution for those with
repeat overdose and fatal overdose (p<0.01). While males more often experienced a fatal index
overdose there were no significant differences in sex distribution for those with repeated nonfatal
overdose when compared to those with only one nonfatal overdose. Bivariate analysis also
suggests that those with repeated overdose events were significantly more likely to have had a
mental health or substance abuse diagnosis when compared to those with only one nonfatal
overdose (p<0.01). Similarly, those who died on their index overdose less frequently had any
documented social code (p<0.01). Those who died on their first overdose were more likely to
have a diagnosis for chronic pain in comparison to those with one nonfatal overdose (p<0.01).
A multivariable analysis assessing factors associated with category of overdose is provided in
Table 3. Males were more than 50% more likely to experience a fatal overdose when compared
to those with a single nonfatal overdose (OR [Odds ratio] 1.57, 95% CIs [confidence interval]:
1.34-1.83). Patients between the ages of 18-44 years were more likely to experience a fatal index
overdose (OR 7.19, 95% CI: 5.88-8.78) or repeat overdose (OR 2.13, 95% CI 1.76-2.58) when
compared to those who only had record of one single nonfatal overdose. Similarly, patients with
a chronic pain diagnosis prior to their first recorded overdose were significantly more likely to
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experience a fatal overdose (OR 3.96, 95% CI: 3.56-4.42) or repeat overdose (OR 1.15, 95% CI
1.04-1.27). However, patients with a prior history of polysubstance abuse or dependence were
more likely to experience a repeat overdose (OR 1.25, 95% CI: 1.13-1.38) and less likely to
experience a fatal index overdose (OR 0.75, 95% CI: 0.68-0.82) compared to those with one
nonfatal overdose. Patients who were last received MAT was more than one year prior to their
index overdose were 28% more likely to experience a fatal index overdose (OR 1.28, 95% CI:
1.05-1.55). Lastly, the odds of fatal index overdose were significantly lower among those
receiving counseling services prior to their first known overdose (OR 0.35, 95% CI: 0.30-0.40).
2.5 Discussion
Overall, these findings suggest that men were more likely to experience a fatal index overdose
and younger and middle-aged patients (aged 18-64 years) were more likely to experience either a
fatal index overdose or repeat overdose; results that are similar to previously identified
associations [4, 5, 15]. These findings suggest the need for targeted overdose prevention
programs targeting younger to middle aged men.
Similarly, those who experienced either a fatal index or repeat overdose were also more likely to
have a chronic pain diagnosis prior to their index event, underscoring the need for integrated
health care, which is consistent with other research findings [22, 23] and supports the need for
continued efforts to identify and support alternative approaches to management of chronic pain
[62-64]. While the CDC has developed Chronic Pain Guidelines, these findings suggest the need
to amplify risk management of chronic pain patients by additional education or co-prescription
of naloxone [65].
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Interestingly, patients with a mental health diagnosis or polysubstance abuse/dependence were
more likely to experience a repeat overdose and less likely to experience a fatal index overdose
when compared to those with a single nonfatal overdose. Although there is evidence that mental
health diagnoses are more prevalent among those who experience an overdose, this is the first
study to identify a difference in magnitude in the associations between mental health diagnosis
and category of opioid overdoses [33, 66]. This is an interesting and important finding
considering previous reports that suggests repeat overdose trends are increasing [39]. Healthcare
systems should be ready for the potential for a higher number of patients and consider integrating
mental health services with emergency care and substance abuse treatment.
In addition to one or more mental health diagnoses, receiving counseling services prior to the
index overdose was protective against experiencing a fatal index overdose. Conversely, those
who received their last MAT services a year or more ago were more likely to experience a fatal
index event during our study period. These findings highlight the need for healthcare systems to
treat OUD using a disease model approach and suggest the need for relapse prevention in
primary care settings [67]. Substance use disorder (SUD) is a chronic disease with relapse rates
comparable to other common health conditions, such as hypertension [68-72]. Future clinical
efforts should be supported to identify and address SUD in primary care settings similar to other
chronic diseases.
Strengths and limitations
To the best of our knowledge, this is the first study to compare risk factors by category of opioid
overdose history. This study used data from one of the largest integrated healthcare systems in
the United States. However, this study is not without limitations. The information collected on
category of overdose which relies on clinical recording and may not be present if an individual
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does not seek medical care for an overdose or a clinician does not document the event.
Therefore, the true number of overdoses may be underestimated. This analysis was conducted
among the veteran population and results from this study may not be generalizable to the general
population. The associations with measures of social determinants of health explored in this
study may be biased given that there is evidence that they are more likely to be entered by mental
health professionals, particularly psychiatrists, when compared to other medical specialties [73,
74]. The decision to omit patients who die on a repeat overdose could systematically exclude
characteristics associated with death after multiple overdoses. However, the small number of
cases prevent inclusion as a second category and characteristics among these patients may be
different when compared to those who died on their index overdose. Future research should
consider characteristics associated with mortality among those with multiple overdose events.
It is important to note that various public health interventions have been implemented to reduce
overdose among people at highest risk [16, 75-78]. These efforts have largely been focused on
reducing the excess supply of opioids through education programs, surveillance systems
designed to reduce the availability of prescription opioids (e.g. prescription drug monitoring
programs), and prevention of overdose-related mortality through broad availability of naloxone.
In general, nonfatal and fatal overdoses appear to be impacting younger and middle aged
veterans, suggesting that primary prevention efforts in the future may want to tailor the programs
to this audience. Chronic pain, psychiatric diagnoses, and contextual factors appear differentially
associated with fatal index overdose in comparison to those with repeated nonfatal overdoses.
These findings underscore the need for integrated healthcare to address mental health and
chronic pain among patients at risk for an opioid overdose.
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Table 1. Demographic and diagnostic characteristics of veterans with a documented opioid
overdose, 2011-2015

Demographic

n (n=12,848)

%

1,098

8.55

Male

11,750

91.45

18-44

3,879

30.19

7,874

61.29

65+

1,095

8.52

No

3,907

30.41

Yes

8,941

69.59

No

5,719

44.51

Yes

7,129

55.49

No

6,327

49.25

Yes

6,521

50.75

No

11,978

93.23

870

6.77

Sex
Female

Age (years)
45-64

Type of pain diagnosis prior to index OD
Any chronic pain diagnosis

Arthritis

Back pain

Migraines
Yes
Headaches or tension headaches
No

11,075

86.20

Yes

1,773

13.80

No

12,586

97.96

262

2.04

11,804

91.87

Psychogenic
Yes
Neuropathy
No
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Yes

1,044

8.13

No

12,187

94.86

661

5.14

Fibromyalgia
Yes
Mental health diagnosis
Any mental health diagnosis

1,080

8.41

Yes

11,768

91.59

No
Yes

5,041
7,807

39.24
60.76

No

3,145

24.48

Yes

9,703

75.52

No

9,764

76.00

Yes

3,084

24.00

No

6,702

52.16

Yes

6,146

47.84

No

9,333

72.64

Yes

3,515

27.36

No

10,334

80.43

Yes

2,514

19.57

No

11,071

86.17

Yes

1,777

13.83

No

10,090

78.53

2,758

21.47

No

Anxiety

Depressive disorder

Bipolar

PTSD

Adjustment disorder

Schizophrenia or other psychotic disorder

Traumatic stress

Personality disorder
Yes
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Either depression, anxiety, or PTSD diagnosis

1,942

15.12

Yes

10,906

84.88

No

8,640

67.25

Yes

4,208

32.75

No

4,545

35.38

Yes

8,303

64.62

No

7,645

59.50

Yes

5,203

40.50

No

6,968

54.23

Yes

5,880

45.77

No

7,137

55.55

Yes

5,711

44.45

No

10,052

78.24

Yes

2,796

21.76

No

11,873

92.41

975

7.59

11,424

88.92

Yes

1,424

11.08

No

11,764

91.56

1,084

8.44

No

All three diagnosis (depression, anxiety, & PTSD)

Substance abuse/dependence
Any substance abuse/dependence diagnosis

Polysubstance abuse/dependence diagnosis

a

Alcohol abuse or dependence diagnosis

Opioid abuse or dependence diagnosis

Cocaine abuse or dependence diagnosis

Other stimulant abuse or dependence diagnosis
Yes
Medication-Assisted Treatment
Ever had MAT
No

MAT before index overdose
Yes
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MAT more than 1 year before index OD

12,144

94.52

Yes

704

5.48

No

981

7.64

Yes

11,867

92.36

No

1,510

11.75

11,338

88.25

7,766

60.45

Yes

5,082

39.55

No

11,689

90.98

1,159

9.02

7,109

55.33

Yes

5,739

44.67

No

12,690

98.77

158

1.23

9,686

75.39

Yes

3,162

24.61

No

11,794

91.80

Yes

1,054

8.20

No

12,620

98.23

228

1.77

No

Social determinants of health (SDoH)
Any code related to SDoH

Counseling services
Yes
Problems related to housing and economic circumstances
No

Problems related to education and literacy
Yes
Problems related to environmental psychosocial circumstances
No

Problems related to mental and behavioral
Yes
Problems related to social environment
No

Other problems related to primary support group

Problems related to upbringing
Yes
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Abbreviations: OD, overdose; PTSD, post-traumatic stress disorder, SDoH, social determinants of health; MAT,
medication-assisted treatment
a. Polysubstance use or dependence refers to a patient having a diagnosis for more than one substance during the
study period (2011-2105).
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Table 2. Bivariate analysis of demographic and diagnostic characteristics by type of opioid
overdose among veterans, 2011-2015 a
No repeat OD
(n=5,725)

Repeat non-fatal OD
( n=2,659)

n

%

n

%

528

9.22

261

9.82

5,197

90.78

2,398

90.18

p

Fatal index OD
( n=4,464)
n

%

309

6.92

4,155

93.08

p

Demographic
Sex
Female
Male

0.39

<0.01

Age
18-44 years

1,488

25.99

853

32.08

1,538

34.45

45-64 years

3,494

61.03

1,630

61.30

2,750

61.60

743

12.98

176

6.62

176

3.94

65+ years

<0.01

<0.01

Type of pain diagnosis prior to index OD
Any chronic pain diagnosis
No

2,112

36.89

900

33.85

895

20.05

Yes

3,613

63.11

1,759

66.15

3,569

79.95

<0.01

<0.01

Arthritis
No

2,915

50.92

1,269

47.72

1,535

34.39

Yes

2,810

49.08

1,390

52.28

2,929

65.61

<0.01

<0.01

Back pain
No

3,226

56.35

1,440

54.16

1,661

37.21

Yes

2,499

43.65

1,219

45.84

2,803

62.79

0.06

<0.01

Migraines
No
Yes

5,390

94.15

2,489

93.61

4,099

91.82

335

5.85

170

6.39

365

8.18

0.33

<0.01

Headaches or tension headaches
No
Yes

5,042

88.07

2,323

87.36

3,710

83.11

683

11.93

336

12.64

754

16.89

0.36

<0.01

Psychogenic
No

5,647

98.64

2,627

98.80

4,312

96.59
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Yes

78

1.36

32

1.20

152

3.41

0.55

<0.01

Neuropathy
No

5,207

90.95

2,444

91.91

4,153

93.03

518

9.05

215

8.09

311

6.97

Yes

0.15

<0.01

Fibromyalgia
No

5,483

95.77

2,526

95.00

4,178

93.59

242

4.23

133

5.00

286

6.41

Yes

0.11

<0.01

Mental health diagnosis
Any mental health diagnosis
No
Yes

261

4.56

61

2.29

758

16.98

5,464

95.44

2,598

97.71

3,706

83.02

<0.01

<0.01

Anxiety
No

1,920

33.54

772

29.03

2,349

52.62

Yes

3,805

66.46

1,887

70.97

2,115

47.38

<0.01

<0.01

Depressive disorder
No

1,005

17.55

397

14.93

Yes

4,720

82.45

2,262

85.07

1,743

39.05

2,721

60.95

<0.01

<0.01

Bipolar
No

4,232

73.92

1,900

71.46

3,632

81.36

Yes

1,493

26.08

759

28.54

832

18.64

0.02

<0.01

PTSD
No

2,760

48.21

1,502

56.49

2,800

62.72

Yes

2,965

51.79

1,157

43.51

1,664

37.28

<0.01

<0.01

Adjustment disorder
No

3,930

68.65

1,765

66.38

3,638

81.50

Yes

1,795

31.35

894

33.62

826

18.50

0.04

<0.01

Schizophrenia or other psychotic disorder
No

4,277

74.71

2,079

78.19

3,978

89.11

Yes

1,448

25.29

580

21.81

486

10.89

<0.01

<0.01

Traumatic stress
No

4,778

83.46

2,213

83.23

4,080

91.40

53

Yes

947

16.54

446

16.77

384

8.60

0.80

<0.01

Personality disorder
No

4,316

75.39

1,934

72.73

3,840

86.02

Yes

1,409

24.61

725

27.27

624

13.98

<0.01

<0.01

Either depression, anxiety, or PTSD diagnosis
No
Yes

575

10.04

197

7.41

1,170

26.21

5,150

89.96

2,462

92.59

3,294

73.79
<0.01

All three diagnosis (depression, anxiety, & PTSD)
No

3,573

62.41

1,512

56.86

3,555

79.64

Yes

2,152

37.59

1,147

43.14

909

20.36

<0.01

<0.01

Substance abuse/dependence
Any substance abuse/dependence diagnosis
No

1,897

33.14

661

24.86

1,977

44.29

Yes

3,828

66.86

1,998

75.14

2,487

55.71

<0.01
Polysubstance abuse/dependence diagnosis

<0.01

b

No

3,337

58.29

1,323

49.76

2,985

66.87

Yes

2,388

41.71

1,336

50.24

1,479

33.13

<0.01

<0.01

Alcohol abuse or dependence diagnosis
No

2,993

52.28

1,239

46.60

Yes

2,732

47.72

1,420

53.40

2,736

61.29

1,728

38.71

<0.01

<0.01

Opioid abuse or dependence diagnosis
No

3,070

53.62

1,189

44.72

2,878

64.47

Yes

2,655

46.38

1,470

55.28

1,586

35.53

<0.01

<0.01

Cocaine abuse or dependence diagnosis
No

4,509

78.76

1,945

73.15

3,598

80.60

Yes

1,216

21.24

714

26.85

866

19.40

<0.01

0.02

Other stimulant abuse or dependence diagnosis
No
Yes

5,225

91.27

2,371

89.17

4,277

95.81

500

8.73

288

10.83

187

4.19

<0.01

<0.01

Medication-Assisted Treatment
Ever had MAT
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No

5,097

89.03

2,264

85.14

4,063

91.02

628

10.97

395

14.86

401

8.98

Yes

<0.01

<0.01

MAT before index OD
No

5,297

92.52

2,398

90.18

4,069

91.15

428

7.48

261

9.82

395

8.85

Yes

<0.01

0.01

MAT more than 1 year before index OD
No

5,433

94.90

2,476

93.12

4,235

94.87

292

5.10

183

6.88

229

5.13

Yes

0.95

<0.01
Social determinants of health
Any code for social determinant of health
No
Yes

237

4.14

120

4.51

5,488

95.86

2,539

95.49

624

13.98

3,840

86.02

0.43

<0.01

Counseling services
No
Yes

450

7.86

200

7.52

860

19.27

5,275

92.14

2,459

92.48

3,604

80.73

0.59

<0.01

Problems related to housing and economic circumstances
No

3,482

60.82

1,535

57.73

2,749

61.58

Yes

2,243

39.18

1,124

42.27

1,715

38.42
0.43

<0.01
Problems related to education and literacy
No

5,143

89.83

2,398

90.18

4,148

92.92

582

10.17

261

9.82

316

7.08

Yes

0.25

<0.01

Problems related to environmental psychosocial circumstances
No

2,901

50.67

1,396

52.50

2,812

62.99

Yes

2,824

49.33

1,263

47.50

1,652

37.01

0.12

<0.01

Problems related to mental and behavioral
No
Yes

5,653

98.74

2,618

98.46

72

1.26

41

1.54

4,419

98.99

45

1.01

0.29

0.24

Problems related to social environment
No

4,111

71.81

1,975

74.28

3,600

80.65

Yes

1,614

28.19

684

25.72

864

19.35

0.02

<0.01

Other problems related to primary support group
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No
Yes

5,193

90.71

2,427

91.27

4,174

93.50

532

9.29

232

8.73

290

6.50

0.40

<0.01

Problems related to upbringing
No
Yes

5,603

97.87

2,611

98.19

4,406

98.70

122

2.13

48

1.81

58

1.30

0.33
<0.01
Abbreviations: OD, overdose; PTSD, Post-Traumatic Stress Disorder; MAT, Medication-Assisted Treatment
a. Bivariate analysis examined patient characteristics that were different among those with a repeated
overdose and fatal index overdose in comparison to those with only non-fatal overdose.
b. Polysubstance use or dependence refers to a patient having a diagnosis for more than one substance
during the study period (2011-2105).
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Table 3. Multinomial regression analysis of factors associated with type of opioid overdoses
among Veterans, 2011-2015
Repeat OD (n=2,659)

Fatal index OD (n=4,464)

OR

95% CI

OR

95% CI

Sex
Male

0.98

(0.83-1.14)

1.57

(1.34-1.83)

Female

1.00

Ref

1.00

Ref

2.13

(1.76-2.58)

7.19

(5.88-8.78)

45-64

1.78

(1.49-2.13)

4.78

(3.95-5.78)

65+

1.00

Ref

1.00

Ref

Chronic pain diagnosis
Yes

1.15

(1.04-1.27)

3.96

(3.56-4.42)

No

1.00

Ref

1.00

Ref

Mental health diagnosis
Yes

1.54

(1.15-2.07)

0.18

(0.15-0.22)

No

1.00

Ref

1.00

Ref

Yes

1.25

(1.13-1.38)

0.75

(0.68-0.82)

No

1.00

Ref

1.00

Ref

MAT more than 1 year prior to index OD
Yes

1.18

(0.97-1.44)

1.28

(1.05-1.55)

No

1.00

Ref

1.00

Ref

Received counseling services
Yes

0.93

(0.78-1.12)

0.35

(0.30-0.40)

Age (years)
18-44

Polysubstance abuse or dependence a

1.00
Ref
1.00
Ref
No
Abbreviations: OR, Odds Ratio; CI, Confidence Interval; OD, overdose; MAT, Medication-Assisted Treatment
a. Polysubstance use or dependence refers to a patient having a diagnosis for more than one substance during
the study period (2011-2105).
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Supplement Table 1. Corresponding ICD-9 and ICD-10 Codes for Variables
Characteristic

ICD-9 and ICD-10 code

Psychosocial & related mental health diagnoses
Any mental health diagnosis

ICD-9: 290.00 to 319.99, excluding tobacco codes starting with 305
ICD-10: F00 to F99, excluding tobacco codes starting with F17

Anxiety

ICD-9: 300
ICD-10: F40, F41

Depression

ICD-9: 296.2, 296.3, 300.4, 311
ICD-10: F32, F33, F34.1

Bipolar

ICD-9: 296.0, 296.1, 296.4, 296.5, 296.6, 296.7, 296.8
ICD-10: F31

PTSD

ICD-9: 309.81
ICD-10: F43.1

Adjustment disorder
Schizophrenia or other psychotic
disorders
Traumatic stress
Personality disorder
Opioid abuse/dependence
Alcohol abuse/dependence
Cannabis abuse/dependence
Sedative, hypnotics, or anxiolytic
abuse/dependence
Cocaine abuse/dependence
Other stimulant abuse/dependence
Hallucinogen abuse/dependence
Any substance abuse/dependence
Polysubstance abuse/dependence

TBI

ICD-9: 309.0, 309.24, 309.28, 309.3, 309.4, 309.9
ICD-10: F43.20- F43.25
ICD-9: 295.90, 295.40, 295.70, 297.1, 297.3, 298.8, 293.81, 293.82,
298.9
ICD-10: F20.9, F20.81, F25.0, F25.1, F22, F24, F23, F06.2, F06.0, F29)
ICD-9: 308.9, 309.89, 309.9
ICD-10: F43.0 F43.8, F43.9
ICD-9: 301.83, 301.7, 301.81, 301.50, 301.4, 301.82, 301.6, 301.0,
301.20, 310.1 301.9
ICD-10: F60, F61
ICD-9 codes: 304.0, 304.7, 305.5
ICD-10 codes: F11
ICD-9: 303, 305.0
ICD-10: F10
ICD-9: 304.3, 305.2
ICD-10: F12
ICD-9: 304.1, 305.4
ICD-10: F13
ICD-9: 304.2, 305.6
ICD-10: F14
ICD-9: 304.4, 305.7
ICD-10: F15
ICD-9: 304.5, 305.3
ICD-10: F16
Any diagnosis for substance abuse/dependence
At least two combinations of the substance abuse/dependence diagnosis
ICD-9: 800.0-801.9, 803.0-804.9, 850.0-854.1, 950.1-950.3, 995.55,
959.01
ICD-10: S02.0, S02.1, S02.8, S02.91, S04.02, S04.03, S04.04, S06,
S07.1, T74.4
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Medication-Assisted Treatment (MAT)
Record of MAT

Using stop code 523 (primary or secondary stop code) to identify MAT
services

Chronic pain before index OD
Back pain

Arthritis
Migraines
Headaches or tension headaches

ICD-9: 720.0-724.9
ICD-10: M45.9- M46.1, M46.90, M47.812, M47.12, M47.814, M47.817,
M48.20, M48.10, M48.30, M48.9, M50.20, M51.9, M50.30, M51.34M51.37, M48.02, M54.2, M53.0, M53.1, M54.12, M54.13,M43.6,
M54.02, M67.88, M53.82, M54.6, M54.5, M54.30, M54.14-M54.17,
M54.89-M54.9, M43.27, M43.28, M53.2X7, M53.3, M54.08, M43.8X9,
M53.9
ICD-9: 710.0-739.9, excluding back pain codes
ICD-10: M00-M02, M36.2, M36.3, M12, M35.3, M15, M16-M19, M05M08, M1A, M10-M14
ICD-9: 346.0-346.9
ICD-10:G43.0, G43.1, G43.4, G43.5, G43.6, G43.7, G43.8, G43.9,
G43.A, G43.B, G43.C, G43.D
ICD-9: 784.0 and 307.81
ICD-10: G44.1, R51, G44.209

Psychogenic

ICD-9: 307.80 and 307.89
ICD-10: F45.41, F45.42

Neuropathy

ICD-9: 355.0, 355.9, 356.0, 357.2, 357.9
ICD-10:G57.00, G58.9, G60, E08.42, E09.42, E10.42, E11.42, E13.42,
G61.9
ICD-9: 729.1
ICD-10: M60.9, M79.1, M79.7

Fibromyalgia
Any chronic pain diagnosis

Any of the diagnoses for chronic pain

Social determinants of health (SDoH) codes prior to index OD
Problems related to housing and
economic circumstances

ICD-9: V60.0, V60.1, V60.89, V60.6, V60.2, V60.9
ICD-10: Z59 (Z59.0-Z59.9)

Problems related to support group,
including family and relationships

ICD-9: V61.0, V61.05, V61.8, V61.01, V61.06, V61.07, V61.08,
V62.82, V61.03, V61.49, V61.02, V61.41, V61.3, V61.04, V61.09,
V61.8, V61.9
ICD-10: Z63 (Z63.0-Z63.9)
ICD-9: V60.3, V62.4, V62.89
ICD-10: Z60.0, Z60.2, Z60.3, Z60.4, Z60.5, Z60.8, Z60.9

Problems related to social
environment
Problems related to upbringing

ICD-9: V61.29, V61.8, V60.81
ICD-10: Z62.0, Z62.1, Z62.2, Z62.3, Z62.6, Z62.8

Problems related to environmental
psychosocial circumstances

ICD-9: V62.5, V62.89, V62.81, V62.9
ICD-10: Z65.0, Z65.1, Z65.2, Z65.3, Z65.4, Z65.5, Z65.8, Z65.9

Problems related to abuse

ICD-9: V61.21, V61.22, V62.83, V61.11, V61.12, V65.49
ICD-10: Z69.0, Z69.01, Z69.02, Z69.1, Z69.8

Counseling services

ICD-9: V65.49, V61.2, V61.1, V65.40, V65.9
ICD-10: Z71.81, Z71.89, Z71.9

Other problems related to mental
and behavior

ICD-9: V40.0, V40.2, V40.3, V40.31, V40.39, V40.9
ICD-10: F48.9, F69
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Any SDoH

Any of the above SDoH codes captured before index OD

Abbreviations: ICD, International Classification of Disease; ICD-9, International Classification of Disease, Ninth
Edition; ICD-10, International Classification of Disease, Tenth Edition; PTSD, Post-traumatic stress disorder; TBI,
Traumatic Brian Injury; MAT, Medication-Assisted Treatment; OD, overdose; SDoH, social determinant of health
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Chapter 3
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3.1 Abstract
Objective
To determine the conditional probability of repeat overdose among patients with one or more
prior overdose events and corresponding probability of overdose mortality.
Methods
Clinical records were extracted between 2011 through 2015 for veterans receiving medical care
from the Veterans Health Administration (VHA). Vital status was determined by linking data
from the patient’s medical record to information contained in the VA/DoD Joint Suicide (allcause) Data Repository (SDR). Conditional probability of repeated overdose and mortality was
calculated among patients with at least one recorded overdose.
Results
There were 12,905 veterans with at least one opioid overdose between 2011 and 2015. Among
this study sample, one fifth (n=2,716) had a repeated opioid overdose during the study period.
The conditional probability for repeated overdose more than doubled for each overdose event
from 21.1% for a second overdose to 43.2% for five or more overdoses. Mortality was highest
for the first documented overdose (34.6%).
Conclusion
Overdose prevention efforts should be expanded and include primary prevention efforts targeting
those at highest risk for overdose morbidity and mortality; including those not currently
receiving treatment for opioid abuse or misuse. Additional research is needed to identify risk
factors for repeated overdose and corresponding mortality to curtail the current opioid crisis.
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3.2 Introduction
Opioid overdoses are a growing public health concern. In the United States, the opioid overdose
mortality rate increased by 413% since 1999, from a rate of 2.9 to 14.9 per 100,000 [1-5]. In
addition to fatal overdoses, nonfatal overdoses resulting in either inpatient admission or
emergency department visits have been substantially increasing in the past decade [6, 7]. Despite
the observed rise in overdoses, little is known about the risk of repeated overdose events and
corresponding mortality. Prior research suggests that a history of overdose and psychiatric
diagnoses are risk factors for repeat overdose among persons who engage in self-harm behavior
or inject drugs [8-11]. However little is understood regarding the risks associated with repeat
overdose among patients in a general patient population.
The overall objective of this study was to calculate the conditional probability of a repeat opioid
overdose event and mortality for each overdose event among veterans who use VHA services.
This research is important because it will elucidate the number of documented opioid overdose
events a patient experiences and will identify the overdose event associated with highest
overdose mortality using data from the largest integrated health care system in the U.S..
3.3 Methods
Sample design
This study cohort included 13,333 veterans with at least one documented opioid overdose
between January 1, 2011 and December 31, 2015. Opioid overdoses were extracted using clinical
records from the VHA Corporate Data Warehouse (CDW) [12]. CDW records were linked with
mortality records from the VA/DoD Suicide (all-cause) Data Repository using Social Security
Numbers (SSNs) [13, 14]. Vital status was determined for these patients through the 2015
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calendar year. Sex and age were extracted from clinical and mortality files. Age was static and
determined on the start of the study period (January 1, 2011).
Opioid overdose
An opioid overdose was identified using International Classification of Disease, Ninth Edition
(ICD-9) codes: 965.00-965.02, 965.09, E850.0-E850.2 and ICD Tenth Edition (ICD-10) codes:
X40-X44, Y10-Y14 and secondary axis codes T40.0- T40.4, and T40.6. The first opioid
overdose documented in the clinical records between calendar years 2011 to 2015 was used as
the index overdose. Repeat overdose was defined as a second documented overdose that either
occurred two days after the previous overdose with the overdose documented as the principal
diagnosis or a second documented overdose that occurred or more than three days after the prior
overdose.
The study sample was restricted to veterans between 18 and 90 years old. To allow time for
repeated events, we excluded patients that had no follow-up visits within one year of the first
overdose event or had their first overdose in the last three months of the study period (October 1,
2015-December 1, 2015). For this study, we excluded patients with an opioid overdose death that
was classified as intentional or homicide, yielding a total of 12,905 patients.
This study was reviewed and approved by the Institutional Review Board at the Syracuse VA
Medical Center, New York.
Analysis plan
The frequency and conditional probability of nonfatal and fatal overdose were estimated among
the total VHA patient population with at least one overdose event during the study period (20112015). Conditional probability of an overdose was calculated by dividing the proportion of
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patients experiencing the event by the number of patients at risk for the event [15-17]. The
conditional probability of interest was mortality at each overdose event for each disease event
(e.g., one, two, three, four or more overdoses) as well as conditional probability for repeated
nonfatal overdose event. Conditional probabilities for overdose death and repeat overdose at
each disease event were estimated and 95% confidence intervals were extrapolated using the
normal approximation method.
3.4 Results
There were 12,905 veterans with at least one overdose event documented in VHA’s electronic
medical record (EMR). The conditional probability of repeated overdose increased directly with
the number of overdose events. The conditional probability for repeated overdoses more than
doubled from 21.1% following one nonfatal overdose event to 43.2% for experiencing four or
more overdoses (Table 1). In total, 4,521 veterans experienced a fatal overdose; accounting for
35.0% of the VHA patients with a recorded overdose. The proportion of deaths was highest for
the first documented overdose (98.8%) compared to subsequent fatal overdose events (Figure 1).
3.5 Discussion
More than twenty percent of patients with a documented opioid overdose had at least one
repeated overdose documented in the records during the five year study period (January 1, 2011December 31, 2015). With every overdose event, the probability of experiencing an additional
overdose continued to increase but the probability of overdose death was consistently low.
Patients were 17 times more likely to die from an opioid overdose on their first documented
overdose event during the study period. Given that overdose mortality was highest among
patients with no prior overdose during this time period, prevention efforts should be focused on
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amplifying resources to those without documented overdose risk. Additional research is needed
to understand the risks associated with repeat overdose to inform future clinical and public health
interventions directed at those with history of multiple overdoses.
Although overdose was obtained from one of the nation’s largest healthcare records, this study
has several limitations. Findings relied on patients seeking medical care for an overdose which
could underestimate the true number of overdoses an individual experienced. Data collected was
among the veteran population so results may not be generalizable to the general population or
users of other health systems. Additional studies are needed to understand if these results hold
true in other healthcare populations. Due to the limited scope of this analysis additional factors
may be present which in turn increase the risk of repeat overdose and associated fatality. Finally
this project only included overdoses that were documented by VHA clinician during the study
period. It is possible that previous overdoses outside of the study period or those were otherwise
undocumented were not captured. Inclusion of these may change distribution across categories or
estimated conditional probabilities.
These results suggest the need for additional research, specifically examining potential unique
risk factors for experiencing a repeat overdose. Given the rates of repeat overdose increased in a
linear fashion, these findings suggest that healthcare systems should be ready for an influx in
patients with opioid overdoses. Furthermore, these findings underscore the urgent need to
expand overdose prevention efforts, such as naloxone distribution to patients with no history of
an overdose.
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Table 1. Repeated opioid overdoses and subsequent mortality among patients between 2011-2015

No. of overdoses
One overdose
Two overdoses
Three overdoses
Four overdoses
More than 5 overdoses

No. of
fatal
OD
4,464
30
15
8
4

Conditional
probability
No. of of repeated
OD a
OD
12,905
2,716
21.05
954
35.13
396
41.51
171
43.18

95% CI of
repeated event a
(20.35-21.76)
(33.33-36.96)
(38.37-44.72)
(38.27-48.23)

Probability
of overdose
mortality
34.59
1.10
1.57
2.02
2.34

95% CI of
mortality a
(33.77-35.42)
(0.76-1.59)
(0.92-2.64)
(0.94-4.10)
(0.75-6.26)

Abbreviations: OD, overdose; CI, confidence interval; No., Number
a. Number of total overdoses indicate the total number of overdoses a patient experienced during the study period.

68

Figure 1. Mortality for each opioid overdose event recorded, 2011-2015

Percent (%) of mortality for each documented overdose event

Opioid overdose mortality for each recorded opioid overdose, 2011-2015
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Probability of overdose mortality with 95% CI

Abbreviations: CI, Confidence Interval
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Chapter 4
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4.1 Abstract
Objective
To identify cause-specific mortality rates and calculate standardized mortality rate ratios (SMRs)
among veterans with a prior nonfatal opioid overdose.
Methods
We followed 8,370 veterans who received medical care for a nonfatal opioid overdose between
January 1, 2011 and December 31, 2015 or date of death, whichever occurred first. Mortality
records were extracted from the Department of Veteran Affairs (VA)/Department of Defense
(DoD) Joint Suicide (all-cause) Data Repository (SDR) and linked to clinical records from the
Veterans Health Administration (VHA). We compared the mortality rates among those with a
nonfatal opioid overdose to a 5% stratified random sample of patients accessing services during
the same time period (n=325,073). SMRs were calculated using age-adjusted cause-specific
mortality rates for the general U.S. population obtained from the Centers for Disease Control and
Prevention’s Wide-Ranging Online Data for Epidemiologic Research (CDC WONDER).
Results
The study cohort included 8,370 veterans with history of a nonfatal opioid overdose resulting in
a total of 39,207 person-years of follow-up. The crude mortality for veterans with a history of a
nonfatal overdose was 370.6 per 10,000 person years and SMR was 26.2 (95% CI [confidence
interval]: 24.6-27.6). The most common causes of death among these veterans of interest were
deaths associated with the circulatory system (26.7%), cancer (19.3%), deaths associated with
the respiratory system (13.1%) and drug-related deaths (11.6%). Those with a prior nonfatal
overdose had a higher risk of substance-related mortality (aHR [adjusted Hazard Ratio] 5.0, 95%
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CI 4.4-5.8), including a higher risk of death from drugs (aHR 6.9; 95% CI 5.8-8.1) and alcohol
(aHR 2.7, 95% CI 2.1-3.6). For cause-specific mortalities assessed between veterans and the
general U.S. population, SMRs were also highest for deaths associated with substances (114.0,
95% CI 98.8-128.7), including drugs (139.3, 95% CI 118.6-160.7) and alcohol (72.7, 95% CI
53.5-92.4). As expected, SMRs for viral hepatitis (107.4, 95% CI 65.5-152.7) and liver cancers
(68.2, 95% CI 47.9-88.7) were substantially higher when compared to rates for these outcomes in
the U.S. general population. Other cause-specific diseases that were elevated included suicide
(29.0, 95% CI 20.0-38.2) and HIV (34.9, 95% CI 10.7-58.9). Deaths related to the digestive
system (45.2, 95% CI 36.7-53.7) and respiratory system (35.4, 30.4-40.4) were also markedly
higher than the general population.
Conclusion
Veterans with a prior nonfatal overdose experienced a substantially higher mortality rate when
compared to other veterans or the general U.S. population. Specific causes of death that were
significantly higher include those related to substance use and mental health, highlighting the
importance of integrated treatment and recovery services for patients with record of one or more
opioid overdose. The significant increase in suicide deaths among veterans, especially among
those with history of a prior overdose, supports the need for continued mental health screenings.
These findings highlight the need for additional research examining substance use, in particular
polysubstance use and associated risk for subsequent mortality among persons with history of
one or more nonfatal overdose. Future research should consider whether associations identified
in these analyses are different for patients from other health care systems or for those without
history of U.S. military service.
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4.2 Introduction
Overdoses have surged in the past decade and are now the leading cause of accidental death in
the United States. More than 60% of overdose deaths across the nation can be attributed to
opioids[1] [2-5]. Between 2007 and 2017 the opioid overdose death rate more than doubled,
from 6.1 per 100,000 to 14.9 per 100,000 [6]. Around the same time, nonfatal opioid overdoses
resulting in inpatient and emergency department visits substantially increased, by more than 60%
and 99% respectively[7]. The rise in opioid overdoses across the United States has been
estimated to cost more than $740 million annually [8]. Despite the recent surge of nonfatal
overdoses and associated mortality associated with opioid abuse/misuse, little is known
regarding the patterns of mortality following a nonfatal opioid overdose.
People who inject drugs (PWID), people diagnosed with an opioid use disorder (OUD) and those
taking more than 90 morphine milligram equivalent (MME) are at highest risk for experiencing
an opioid overdose [9-12]. Although overdoses are the leading cause of death among PWID,
research has found that PWID more often die from infection-related causes such as human
immunodeficiency virus (HIV), Hepatitis C (HCV), and other substance-related deaths [13-15].
Similarly, research suggests that people with an OUD more often die from infectious disease and
liver disease when compared to the general population [13, 16]. Patients taking a high volume of
MME are often suffering from terminal cancer or chronic diseases associated with severe pain
[9, 12, 17]. Several public health interventions have been developed to encourage safer
prescribing practices and educate patients on opioid use, especially for those with high MME
such as those with chronic non-cancer pain [9, 18]. Although many of these programs have been
found to reduce the supply of prescription opioids [11], there is still little known regarding the
complex nature of overdose and subsequent mortality. Research among Medicaid enrollees
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suggests that mortality following a nonfatal overdose are often associated with substances,
suicide, cancer, and the circulatory system however, cause-specific mortality among veterans
using VHA services has yet to be examined [19]. The overarching objective of this study is to
assess the cause specific mortality among veterans with a documented nonfatal opioid overdose.
In order to describe the mortality for specific causes of deaths among veterans with a nonfatal
overdose, we will examine the mortality following a nonfatal overdose to a comparison group
comprised of a 5% random sample of other veterans using VHA services. We will then compare
the mortality among veterans with a nonfatal opioid overdose to the general population.
Given previous research examining mortality among veterans with an OUD, we expected
substance-related deaths to be significantly higher among this population [13, 16, 19-21]. We
also expected suicide death rates to be substantially higher given that veterans have almost
double the suicide death rate than the general population and previous research suggest that
people with a history of a nonfatal overdose had higher suicide death rates [19, 22, 23].
Similarly, we expected deaths attributed to hepatitis to be significantly higher among our veteran
cohort, given that prevalence of hepatitis is two-times higher than non-veterans and is higher
among those with a history of drug use [13, 16, 24-26].
4.3 Methods
In order to determine mortality following a nonfatal overdose among veterans, we examined
causes of death linking clinical and mortality files from the Veterans Health Administration
(VHA), which is the largest integrated healthcare provider in the United States. We extracted
records on individuals with a documented opioid overdose between January 1, 2011 and
September 30, 2015 and identified corresponding causes of death, if any, among this cohort.
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The study cohort examined clinical and death records for 10,522,835 records to identify veterans
with a documented opioid overdose and veterans with no documented overdose for the
comparison group. Veterans were identified as having an opioid overdose using clinical records
from the VHA Corporate Data Warehouse (CDW)[27]. CDW records were linked with the
VA/DoD Suicide Data Repository, using Social Security Numbers (SSNs)[28, 29]. Sex and age
were extracted from the SDR and CDW. Age was fixed and determined at the start of the study
period. Age-adjusted mortality rates for each cause of death of interest were pulled from the
Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic
Research (CDC WONDER) Detailed Compressed Mortality Files from 2011 through 2015 [6].
To more precisely compare age-adjusted mortality rates with the veteran population we pulled
age-adjusted rates among 15-84 year old U.S. residents using CDC WONDER.
This study was reviewed and approved by the Institutional Review Board at the Syracuse VA
Medical Center, New York.
Study sample
A nonfatal opioid overdose was identified using International Classification of Disease, Ninth
Edition (ICD-9) codes: 965.00-965.02, 965.09, E850.0-E850.2 and ICD Tenth Edition (ICD-10)
codes: X40-X44, X60-X64, X85, Y10-Y14 with secondary axis codes: T40.0-T40.4 and T40.6.
The first opioid overdose documented in the clinical records was used as the index overdose.
Those who died from a fatal index overdose were excluded from analyses.
A control group was constructed by extracting a 5% random sample of veterans, stratified by sex
and age. Age was collapsed into three categories: ages 18-44, 45-64 and over 65 years old.
Pulling a stratified random sample allowed the control group to be similar in composition to
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those with a nonfatal overdose[30]. Given that VHA users are primarily older males, we
intentionally stratified by sex and age to reduce potential bias that may influence observed
mortality among the control group. The use of stratified random sample control populations has
been used in previous research among the VHA patient population [20, 31, 32].
Exclusion criteria
The study cohort was restricted to veterans between 18 and 90 years old. We excluded patients
that had no follow-up visits within one year of the first overdose event or had a nonfatal
overdose in the last three months of the study period (October 1, 2015 - December 1, 2015). This
mitigated potential bias among those with less than three months of risk for mortality. After
applying this inclusion and exclusion criteria, 8,370 veterans were identified for the nonfatal
overdose group and 325,073 veterans with no documented overdose as the comparison group.
Mortality
We evaluated mortality from January 1, 2011 through December 31, 2015. Follow-up for the
study ended the day the veteran died or the end of the study period, whichever occurred first. In
addition to all-cause mortality, cause-specific mortality was considered for the following: all
external causes of death, suicide, homicide, accidents, substance-related deaths, drug-related
deaths, alcohol-related deaths, infectious, viral hepatitis, human immunodeficiency virus (HIV),
circulatory system, respiratory system, influenza, chronic respiratory disease, digestive system,
cirrhosis and alcoholic liver disease and cancers. Specific types of cancers were categorized into
the following groups using the International Classification of Diseases for Oncology[33]: lung
and bronchus, liver and intrahepatic bile duct, digestive system cancers, which included
esophageal, stomach, small intestine, colon, rectal, anal, gallbladder and pancreatic cancers,
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lymphoma and leukemia and other cancers. (See Supplement Table 1 for the full list of causespecific mortality and corresponding ICD-10 codes).
Analysis
We identified person-years of follow-up and mortality rates per 10,000 person-years for the
entire cohort to compare mortality among veterans with a history of nonfatal overdose to a
comparison group of veterans. Crude death rates were calculated and mortality rates were
estimated using Cox proportional hazard models, adjusting for age and sex. Survival curves were
relatively close, indicating the hazard ratio remained constant over time [34]. Adjusted hazard
ratios [aHR] and corresponding 95% confidence interval [CI] were calculated for cause-specific
mortality.
We calculated the standardized mortality rate ratios (SMRs) to compare the observed number of
deaths among our overdose cohort to the number of expected number based on rates of mortality
among members of the U.S. general population [35, 36]. The expected number of deaths was
calculated using age-adjusted mortality rates from CDC WONDER and corresponding cohort
size[6].
Alpha was set to 0.05 for all statistical tests. We analyzed data using SAS Enterprise Grid
software (version 5.1, SAS Institute Inc.).
4.4 Results
This study identified 8,370 veterans with a history of nonfatal opioid overdose and a total followup of 39,207 person-years. Among this cohort of veterans with history of a nonfatal overdose,
approximately 17.4% (n=1,453) experienced death during the follow-up period. The proportion
of veterans who died following a nonfatal overdose was similar to the proportion of veterans
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who died in the control group (17.6%, n=57,099). Despite the similar proportion of deaths
among each group, there were distinct differences in cause-specific mortality rates and
corresponding SMRs. The overall crude mortality rate for veterans with a prior overdose was
370.6 per 10,000 person-years and for the control group was 384.1 per 100,000 person-years.
Compared to the control group, veterans with a nonfatal opioid overdose had a higher risk of allcause mortality after adjusting for age and gender (aHR 1.5; 95% CI 1.4-1.5). (Table 1)
The most common causes of death among veterans with a prior nonfatal overdose were disorders
of the circulatory system (26.7%), cancer (19.3%), respiratory disorders (13.1%), and drugrelated deaths (11.6%). The veteran cohort with a prior nonfatal overdose was more than six
times likely to die from substance-related diseases (aHR [Adjusted Hazard Ratio] 5.0, 95% CI [
Confidence Interval]: 4.4-5.8) and more than six times (aHR 6.9, 95% CI 5.8-8.1) likely to die
from drug-related diseases compared to their veteran peers. These veterans were more than three
times as likely to die from hepatitis (aHR 3.2, 95% CI: 2.1-4.9) and cirrhosis or alcoholic liver
disease than their veteran peers (aHR 3.1, 95% CI: 2.4-3.9). Veterans with a prior overdose were
also more than two times more likely to die from suicide than their veteran peers (aHR 2.2, 95%
CI: 1.6-3.1). Further, these veterans were twice as likely to die of diseases associated with the
digestive system (aHR 2.3, 95% CI: 1.9-2.8), chronic respiratory disease (aHR 2.2, 95% CI: 1.63.1) and HIV (aHR 2.6, 95% CI: 1.3-5.4).
Similarly, they had an elevated risk of death from viral hepatitis (aHR 3.2, 95% CI 2.1-4.9) and
cirrhosis and alcoholic liver disease (aHR 3.1, 95% CI 2.4-3.9). These veterans had a higher risk
of death attributed to HIV (aHR 2.6, 95% CI 1.3-5.4), cancer of the liver or intrahepatic bile duct
(aHR 2.3, 95% CI 1.7-3.2), or death associated with the digestive system (aHR 2.3, 95% CI 2.3,
95% CI 1.9-2.8). Of note, death from suicide was markedly higher among veterans with a prior
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nonfatal overdose compared to the control group of veterans (aHR 2.2, 95% CI 1.6-3.1).
Conversely, veterans with history of an overdose were significantly less likely to die from
lymphoma or leukemia (aHR 0.5, 95% CI 0.2-0.9) compared to veterans in the control group.
Among cause-specific mortalities assessed and compared to the US population, SMRs were
more than eight times higher among veterans with a prior overdose. SMRs were highest for
deaths associated with substances (114.0, 95% CI: 98.8-128.7); including drugs (139.3, 95% CI:
118.6-160.7) and alcohol (72.7, 95% CI: 53.5-92.4). SMRs for viral hepatitis (107.4, 95% CI:
65.5-152.7) and liver cancers (68.2, 95% CI: 47.9-88.7) were substantially higher among
veterans with history of a nonfatal opioid overdose. Other cause-specific disease that were
elevated in this population include HIV (34.9, 95% CI: 10.7-58.9), suicide (29.0, 95% CI: 20.038.2), and deaths related to the digestive system (45.2, 95% CI: 36.7-53.7). (Table 2)
4.5 Discussion
Veterans with a documented nonfatal opioid overdose died at 26 times the rate of the general
U.S. population aged 15-84 years. Moreover, mortality was markedly higher among veterans
with a prior nonfatal overdose when compared to a comparison population of veterans who use
VHA services or the general U.S. population (aHR 1.46, 95% CI: 1.39-1.54). These findings
suggest that excess mortality among veterans with a prior nonfatal overdose may be associated
with patterns and consequences of substance use. Mortality associated with substance use for
veterans with a prior nonfatal overdose was significantly elevated among those with a prior
nonfatal overdose. The rate of alcohol-related deaths was 72 times higher than the rate of
alcohol-related deaths in the general population.
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Similarly, veterans with a prior nonfatal overdose had noticeably higher rates of death compared
to other veterans, specifically for deaths associated with drugs (aHR 6.85 95% CI: 5.79-8.09),
viral hepatitis (aHR 3.22, 95% CI: 2.11-4.93), cirrhosis and alcoholic liver disease (aHR 3.05,
95% CI 2.38-3.90). These findings suggest excess mortality among veterans with a nonfatal
overdose can be largely attributed to substance abuse. Although deaths associated with substance
use accounted for a majority of deaths, disease of the digestive and respiratory system were
elevated in this population as well. Additional research is need to understand the intersection of
certain comorbidities related to the digestive system and overdose risk.
There were some distinct differences when comparing results from this study to an existing study
examining mortality following a nonfatal overdose among a sample of Medicaid enrollees [19].
The all-cause SMR and drug-related deaths were similar between both the veteran population
and Medicaid enrollees. In general, the cause-specific deaths listed in both studies were elevated
among the veteran population and HIV was the only cause-specific death in both studies that was
lower among the Medicaid population. The most notable difference in our study was the SMR
for alcohol-related deaths, the veteran population had an SMR more than seven times higher than
the study article. Deaths associated with cirrhosis and alcoholic liver disease were more than four
times higher and deaths associated with viral hepatitis were more than three times higher. This
finding may be attributed to high rates of HCV among veterans from the Vietnam Era [24-26].
These findings parallel previous research suggesting a deeper understanding of the complex
relationship between overdose and self-harm [23, 37-39]. Importantly, deaths from suicide were
markedly higher among our cohort of veterans with a prior opioid overdose compared to the
general population and a random sample of veterans from the VHA using population. This
finding alone suggests the need for continued support and comprehensive services aimed at
80

reducing suicide among veterans. Mental health services, such as post-discharge psychiatric care
may benefit patients with history a nonfatal overdose [40-42]. A documented overdose may
provide opportunities to initiate treatment or other prevention programs such as naloxone
distribution or provide mental health screening given the elevated mortality associated with
suicide and substance-related deaths.
Strengths and limitations
Although this study utilized data from one of the nation’s largest healthcare networks, analyses
were contingent on patients seeking medical care for healthcare needs such as an overdose. The
large sample size provided the statistical power needed to detect differences in risk for mortality.
Despite the large sample size, this study had several limitations. Previous studies have shown
that barriers often impede healthcare treatment for OUD, which could influence findings from
this study[43]. Results from this study may underestimate the magnitude of nonfatal overdoses
and subsequent mortality among veterans[44]. Furthermore, these results may not be
generalizable to the US population given the heterogeneous composition of veterans seeking
healthcare [45-47].
Conclusion
Given the rise in opioid overdoses across the US, there is an urgent need to understand excess
mortality among people who experience a nonfatal overdose to inform future clinical and public
health efforts. Veterans with a history of nonfatal overdose are significantly more likely to die
from any cause, specifically deaths associated with substance use and suicide. Additional
research is needed to determine the relationship between psychiatric diagnoses, substance use
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and overdose risk over time. These findings underscore the need for coordinated health care,
with particular emphasis on mental health care among those with a prior overdose.
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Table 1. Mortality rate (per 10,000 person-years) among veterans with a nonfatal index OD (n=8,370) compared to a 5% stratified random sample of veterans
(n=325,073) a
Nonfatal OD

Control group
Hazard
ratio of
mortality
-

95% CI
Hazard
Ratio
-

Adjusted
Hazard
ratio of
mortality b
-

95% CI
Adjusted
Hazard
Ratio b
-

p-value
-

No. of
deaths
59

Crude mortality
rate
15.05

No. of
deaths

Crude
mortality
rate
-

69

17.60

1,509

10.15

1.74*

(1.36-2.21)

1.82*

(1.43-2.32)

<0.001

Suicide

39

9.95

651

4.38

2.27*

(1.65-3.14)

2.24*

(1.62-3.10)

<0.001

Homicide

5

1.28

98

0.66

1.93

(0.79-4.75)

1.71

(0.70-4.23)

0.24

Accidents

25

6.38

760

5.11

1.25

(0.84-1.86)

1.43

(0.96-2.13)

0.08

223

56.88

1,474

9.91

5.74*

(4.98-6.61)

5.03*

(4.36-5.80)

<0.001

Drug-related

169

43.10

871

5.86

7.36*

(6.24-8.68)

6.85*

(5.79-8.09)

<0.001

Alcohol-related

54

13.77

603

4.06

3.40*

(2.57-4.49)

2.73*

(2.06-3.61)

<0.001

55

14.03

1,393

9.37

1.50*

(1.14-1.96)

1.89*

(1.44-2.49)

<0.001

Viral hepatitis

24

6.12

203

1.37

4.48*

(2.94-6.84)

3.22*

(2.11-4.93)

<0.001

HIV

8

2.04

83

0.56

3.66*

(1.77-7.56)

2.63*

(1.27-5.44)

0.01

Circulatory system

388

98.96

18,312

123.17

0.80*

(0.73-0.89)

1.29*

(1.16-1.42)

<0.001

Respiratory system

Cause of death
Opioid overdose
External Cause of death

Substance-related

Infectious

191

48.72

6,730

45.27

1.08

(0.93-1.24)

1.87*

(1.61-2.16)

<0.001

Influenza & pneumonia

23

5.87

1,219

8.20

0.72

(0.47-1.08)

1.32

(0.87-2.00)

0.19

Chronic respiratory disease

139

35.45

4,051

27.25

1.30*

(1.10-1.54)

2.18*

(1.83-2.58)

<0.001

109

27.80

2,036

13.69

2.03*

(1.68-2.46)

2.27*

(1.87-2.75)

<0.001

70

17.85

763

5.13

3.48*

(2.72-4.44)

3.05*

(2.38-3.90)

<0.001

280

71.42

14,585

98.10

0.73*

(0.65-0.82)

1.00

(0.88-1.12)

0.97

Lung & bronchus

80

20.40

4,347

29.24

0.70*

(0.56-0.87)

0.90

(0.72-1.13)

0.38

Liver & intrahepatic bile duct

43

10.97

699

4.70

2.33*

(1.71-3.17)

2.31*

(1.69-3.16)

<0.001

Digestive system

42

10.71

2,780

18.70

0.57*

(0.42-0.78)

0.77

(0.57-1.05)

0.09

Lymphoma & leukemia

9

2.30

1,116

7.51

0.31*

(0.16-0.59)

0.47*

(0.24-0.90)

0.03

Other cancers

106

27.04

5,643

37.96

0.71*

(0.59-0.86)

1.06

(0.88-1.29)

0.55

1,453

370.59

57,099

384.06

0.97

(0.92-1.02)

1.46*

(1.39-1.54)

<0.001

Digestive system
Cirrhosis & alcoholic liver disease
Cancers

Any type of death

Abbreviations: No, Number; CI, Confidence Interval; SMR, Standardized Mortality Rate Ratio; OD, overdose; HIV, human immunodeficiency virus
a. For those with a nonfatal OD there were 39,207 person-years follow-up. A control group was constructed using a 5% random sample of veterans, stratified by sex
and age stratum.
b. Adjusted for age and sex.
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Table 2. Standardized Mortality Ratios, observed, and expected number of deaths for veterans with a nonfatal index overdose for all causes and selected causes, 2011-2015
US Age-adjusted
rates a

Nonfatal OD
No. of deaths

Crude mortality
rate

Opioid overdose

59

15.05

Expected
number of
deaths b
0.91

External Cause of death

69

17.60

4.19

Suicide

39

9.95

Homicide

5

Accidents

Standardized Mortality Rate Ratio
(95% CI)
SMR b

95% CI

64.73

(48.29-81.38)

16.47

(12.58-20.35)

1.34

29.01

(19.97-38.24)

1.28

0.54

9.25

(1.14-17.38)

25

6.38

2.30

10.85

(6.61-15.13)

223

56.88

1.96

113.96

(98.84-128.71)

Drug-related

169

43.10

1.21

139.25

(118.62-160.73)

Alcohol-related

54

13.77

0.74

72.65

(53.51-92.44)

55

14.03

1.65

33.36

(24.52-42.14)

Viral hepatitis

24

6.12

0.22

107.39

(65.45-152.74)

HIV

8

2.04

0.23

34.88

(10.68-58.89)

Circulatory system

388

98.96

15.27

25.41

(22.88-27.94)

Respiratory system

191

48.72

5.40

35.40

(30.35-40.39)

Influenza & pneumonia

23

5.87

0.94

24.45

(14.47-34.47)

Chronic respiratory disease

139

35.45

3.35

41.48

(34.59-48.39)

109

27.80

2.41

45.15

(36.74-53.72)

Cause of death

Substance-related

Infectious

Digestive system

70

17.85

1.07

65.29

(50.09-80.75)

280

71.42

15.29

18.32

(16.17-20.46)

Lung & bronchus

80

20.40

4.17

19.20

(14.98-23.39)

Liver & intrahepatic bile duct

43

10.97

0.63

68.23

(47.85-88.65)

Digestive system

42

10.71

3.14

13.36

(9.33-17.42)

Lymphoma & leukemia

9

2.30

1.06

8.47

(2.94-14.04)

Other cancers

106

27.04

6.14

17.27

(13.98-20.55)

1,453

370.59

55.41

26.22

(24.87-27.57)

Cirrhosis & alcoholic liver disease
Cancer

Any type of death

Abbreviations: No, Number; CI, Confidence Interval; SMR, Standardized Mortality Rate Ratio
a. Mortality for US population was from the Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research data (CDC WONDER).
b. Mortality rates and expected counts is by using age-adjusted mortality rates among 15-84 year olds.
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Supplemental Table ICD-10 Codes for cause-specific mortality
Cause of death

ICD-10 Codes For Underlying Cause of Death

Opioid overdose

X40-X44, X60-X64, X85, Y10-Y14 with secondary axis codes T40.0-T40.4, T40.6

External Cause of death

X60-X84, Y87.0, X85-Y09, Y87.1, V01-X39, X46-X59, Y85-Y86

Suicide

X60-X84, Y87.0

Homicide

X85-Y09, Y87.1

Accidents

V01-X39, X46-X59, Y85-Y86

Substance-related

Drug-related

Alcohol-related
Infectious

F11.0-F11.5, F11.7-F11.9, F12.0-F12.5, F12.7-F12.9, F13.0-F13.5, F13.7-F13.9, F14.0-F14.4,
F14.7-F14.9, F15.0-F15.5, F15.7-F15.9, F16.0-F16.5, F16.7-F16.9, F17.0, F17.3-F17.5, F17.7F17.9, F18.0-F18.5, F18.7-F18.9, F19.0-F19.5, F19.7-F19.9, X40–X44, Y10–Y14, F10, G31.2,
G62.1, I42.6, K29.2, K70, R78.0, X45, Y15
F11.0-F11.5, F11.7-F11.9, F12.0-F12.5, F12.7-F12.9, F13.0-F13.5, F13.7-F13.9, F14.0-F14.4,
F14.7-F14.9, F15.0-F15.5, F15.7-F15.9, F16.0-F16.5, F16.7-F16.9, F17.0, F17.3-F17.5, F17.7F17.9, F18.0-F18.5, F18.7-F18.9, F19.0-F19.5, F19.7-F19.9, X40–X44, Y10–Y14
F10, G31.2, G62.1, I42.6, K29.2, K70, R78.0, X45, Y15
A00-B99

Viral hepatitis
HIV

B15-B19
B20-B24

Circulatory system

I00-I99

Respiratory system

J00-J98

Influenza & pneumonia

J09-J18

Chronic respiratory disease

J40-J47

Digestive system

K00-K92

Cirrhosis & alcoholic liver
disease
Cancer

K70, K73-74
C00-D48

Lung & bronchus

C34

Liver & intrahepatic bile duct

C22

Digestive system

C15-C21, C23-C26

Lymphoma & leukemia

C82-C85, C91-C95

Other cancers

C00-C14, C27-C33, C35-C81, C86-C90, C96-D48

Abbreviations: ICD-10, International Classification of Diseases, Tenth Edition
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5.1. Summary
This retrospective cohort study consisted of 13,333 patients with a documented opioid overdose,
of any type, from January 1, 2011 to December 31, 2015. Among our cohort, 4,949 persons
experienced a fatal overdose during the study period. Of note, we found that mortality from an
opioid overdose was highest for an individual’s index (i.e. first recorded in the electronic medical
record) overdose (98.8%, n=4,890), with only 1.2% (n=59) dying on a repeat overdose. Of those
who survived their first overdose, 31.5% (n=2,659) had one or more repeat overdoses. Among
those with a repeat overdose, we found that the conditional probability of repeat overdose
increased in a linear fashion with the number of additional overdoses in the patient’s medical
records. In other words, the probability of having a fourth overdose was higher than the
probability of having either a third or second overdose.
Although the U.S. has been experiencing an increase in overdoses for more than a decade there is
still a limited understanding of risk for repeat overdose or whether factors associated with
increased risk for repeat overdose are also associated with risk for overdose mortality. To answer
these questions, we identified and compared risk factors for different overdose outcomes,
including repeat overdose, available in VHA’s electronic health record.
Patients between the ages of 18-64 years were the most likely to have record of a repeat overdose
or fatal index overdose compared to those with record of only one non-fatal overdose. Men were
more likely than women to die on their index overdose when compared to either repeat or single
non-fatal overdose. (OR [odds ratio] 1.57, 95% CI [confidence interval]: 1.34-1.83). Similarly,
those with a chronic pain diagnosis were more likely to experience either a repeat overdose (OR
1.15, 95% CI: 1.04-1.27) or fatal index overdose (OR 3.96, 95% CI: 3.56-4.42), when compared
to those with report of only one non-fatal overdose. Surprisingly, we found that patients with a
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mental health and substance abuse/dependence diagnosis were more likely to experience a repeat
overdose and were less likely to die from a fatal index overdose. We also identified associations
between patients receiving counseling prior to an overdose and lower likelihood of experiencing
a fatal overdose (OR 0.35, 95% CI: 0.30-0.40) and those who had been in MAT more than one
year prior were more likely to experience a fatal index overdose (OR 1.28, 95% CI:1.05-1.55).
Neither of these factors were significantly associated with repeat overdose.
Among those with a non-fatal overdose during the study period, we identified significantly
increased rates for all-cause mortality when compared to risk for death among other veterans
receiving VHA services. Veterans with record of a non-fatal overdose were five times (aHR
5.03, 95% CI: 4.36-5.80) more likely to die from substance-related deaths than their veteran
peers. Furthermore, they were more than three times as likely to die from viral hepatitis (aHR
3.22, 95% CI: 2.11-4.93) or cirrhosis and alcohol-related liver disease (aHR 3.05, 95% CI: 2.383.90). Despite the higher rate of suicide among veterans who use VHA services [1-3], those with
a history of an opioid overdose were twice (aHR 2.24, 95% CI: 1.62-3.10) as likely to die from
suicide as their veteran peers who also used VHA services.
Standardized mortality rate ratios (SMR) were calculated to identify differences in the number of
observed deaths to the number of expected deaths for cause-specific mortality in the general U.S.
population. Of the categories examined, veterans with a non-fatal overdose died at more than 139
times the rate of drug-related deaths, more than 114 times the rate for substance-related deaths
and more than 72 times the rate for alcohol-related deaths than the general U.S. population.
Moreover, veterans with a history of an opioid overdose died at more than 100 times the rate
from viral hepatitis, more than 68 times the rate of liver and intrahepatic bile duct cancer, and
more than 65 times the rate for cirrhosis and alcoholic-related liver disease than the general
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population. Overall, we found that veterans with a history of non-fatal overdose died at
approximately 26 times the rate of all-cause mortality than observed in the general population.
Overall, these findings highlight the need for additional public health and clinical interventions
for those at risk of overdose. Prevention programs designed to reduce opioid overdose mortality
should focus on primary prevention efforts, such as reaching veterans who may not have been
identified as having a substance abuse or dependence problem and should tailor these programs
to engage veterans who are young to middle aged adults. These findings suggest healthcare
providers and health system administrators should prepare for a rise in patients with repeat
overdose history and should work to coordinate these patients with mental and physical health
care as needed. Lastly, these findings suggest a need to address excess mortality risk among
people with a history of non-fatal overdose. Findings from this project describe the magnitude of
excess mortality among people with a history of a non-fatal overdose, especially causes of death
related to substances; including drugs or alcohol.
5.2 Significance
In the United States, the opioid overdose death rate nearly doubled in four years between 2013 to
2017 (7.9 to 14.0 per 100,000), highlighting the urgent need to understand ways public health
and clinical efforts can address rising morbidity and mortality associated with opioid abuse and
misuse [4-9]. This study sought to identify the potential differences in risk for non-fatal, repeated
and fatal overdose, which are all of growing concern. To date, little is known about the
magnitude of repeat overdoses that occur within a clinical setting and the overdose event that is
associated with the highest overdose mortality.
Understanding risk factors for fatal overdose and repeat overdose can inform public health and
clinical efforts to combat the rise in mortality and morbidity associated with opioid overdoses.
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The project specifically assessed the number of non-fatal overdoses and risk for mortality or
repeated events. Results from this project parallel findings from previous research, which
suggests the need for additional mental health programs and treatment for those who experience
an opioid overdose. These findings also underscore the need to amplify primary prevention
efforts targeted to those who may not have experienced a previous overdose, specifically those
between the ages of 18 and 64 years.
This study was not without limitations. First, we were only able to examine opioid overdoses that
were documented in VHA’s clinical or mortality records. It is possible that the true number of
opioid overdoses among this patient population was underestimated. Moreover, patients may
have sought health services not associated with VHA, which could also bias results and limit
consideration of associated characteristics. This study was conducted using data from veterans
using VHA healthcare services, who often report a greater number of physical and mental health
conditions compared to the general population [10, 11]. It is possible that patients with different
physical and mental health comorbidities are associated with differential patterns of health care
services and likelihood that overdose history is assessed and recorded. These analyses were
conducted among patients seeking medical care which could lead to Berksonian bias, due to the
difference in overall health among populations studied [12]. However, using comparison groups
and stratifying by potential confounding features such as sex and age aided to reduce potential
bias that may occur. Lastly, using clinical records with mortality files could have resulted in a
missed deaths resulting in an underestimate of true mortality. However, records were required to
match fully on SSN and 80-90% on additional demographics such as name, date of birth, and sex
[2, 13, 14]. Diagnostic codes in clinical records are not always a true representation the number
of patients meeting diagnostic criteria. Clinical records are reliant on medical professionals
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inputting them into the electronic health records therefore certain diagnostic codes, in particular
the social codes, may be underutilized and lead to an underestimate in the patient population [15,
16].
Although this study used clinical records which have inherent limitations, to the best of our
knowledge, this was the first study to explore multiple overdose outcomes and compare risk
factors for category of overdose using a comprehensive list of potential medical and contextual
characteristics including demographic, chronic pain diagnoses, mental health diagnoses, and
social codes, which served as indicators of social determinants of health. Findings from this
study could be useful in informing clinical tools developed by the VA, such as a clinical
dashboard, which is used to identify patients at risk for an adverse event related to opioids, by
integrating contextual factors that may increase a patients risk for experiencing an overdose [1720].
5.3 Future research
These results indicate the need for additional research, specifically among those with cooccurring mental health and substance use disorders. While there are many public health
interventions aimed at reducing the morbidity and mortality associated with overdoses, they have
primarily focused on reducing the excess supply of prescription opioids. While some public
health prevention efforts have demonstrated a reduction in overdose death, such as the
implementation of prescription drug monitoring programs or the development of chronic pain
guidelines, some researchers suggest this has pushed individuals to seek more potent nonprescription opioid options increasing risk for overdose morbidity and mortality [21-23].
Furthermore, public health and clinical interventions have been primarily developed to reduce
the supply of opioids rather than reducing demand. Additional research is needed on initiation of
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substance abuse and misuse and motivation for initial misuse. Findings from this study suggest
that additional comorbidities, specifically mental health comorbidities, may be the underlying
factors driving the current overdose crisis and in turn may be factors associated initial misuse or
abuse. While safer prescribing practices are necessary to mitigate initial abuse or misuse, a highlevel of stigma is present among people with an opioid use disorder (OUD) [24, 25]. Stigmareduction is essential in supporting individuals with a history of substance abuse or dependence,
including reducing the stigma surround seeking treatment for the disease [26]. Although there is
a prolific amount of research showing the effectiveness of Medication-Assisted Treatment
(MAT) for OUD, additional barriers often impede patients from receiving necessary treatment.
Infrastructure barriers such as provider willingness and access to providers who can prescribe
MAT often deter patients from receiving treatment [20, 26-28]. Given our findings, which show
that mortality is highest for the first documented overdose, there is an urgent need to remove
potential barriers that may impede patients from seeking medical resources needed.
Future studies should also examine the conditional probability of repeat overdose and identify
the overdose event that is associated with highest mortality in other populations. Furthermore,
additional research is needed to elucidate the relationship between psychiatric comorbidities and
overdose risk. Mental health diagnosis and related conditions, including substance abuse or
dependence, are suggested to be the driving factors for the rise in opioid overdoses. Because of
this, additional research is also needed to understand the best treatment for individuals with cooccurring mental health diagnoses or a history of polysubstance use.
5.4. Conclusions
Understanding risk of experiencing a fatal overdose or repeated overdose is necessary in order to
curb the current rise in fatal and non-fatal overdoses. These findings underscore the need for
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amplified prevention efforts targeted to those without a history of overdose. Furthermore, these
results suggest that healthcare systems should be ready for a rise in the number of patients seen
for a repeat overdose. While these results suggest that patients with a repeat overdose may be in
need of additional clinical services, coordinated health care is needed among those with a prior
overdose. In order to tackle this multifaceted issue, additional primary care services are needed
in conjunction with mental health care to address the potential comorbidities among those with a
documented or suspected overdose. In conclusion, this study demonstrates that opioid overdoses
remain a significant public health problem with additional research needed however, the current
public health crisis is not driven solely by opioids, rather this appears to be mental health needs
and associated crises. Health systems, clinical health providers, and others seeking to decrease
deaths resulting from opioid overdose, are encouraged to systematically assess for and intervene
on symptoms associated with mental health disorders.
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APPENDIX A
Diagnostic codes used for opioid overdoses recorded in the EHR
Type of
overdose
Opioid
overdose
hospitalization

ICD-9

ICD-10

965.00 (Opium)
965.01 (Heroin)
965.02 (Methadone)
965.09 (Other opiates/narcotics)
OR
E850.0 (Accidental: Heroin
E850.1 (Accidental: Methadone)
E850.2 (Accidental: Other opiates)

T40.0X Opium
T40.1X Heroin
T40.2X Other opioids
T40.3X Methadone
T40.4X Synthetic narcotics
T40.60X Unspecified narcotics
T40.69X Other narcotics
And a 6th character of 1,2,3,or 4

Opioid
overdose
mortality

Underlying cause of death code:
X40-X44 (accidental), X60-X64
(intentional/self-harm), X85
(assault/homicide), Y10-Y14
(undetermined)
And a contribution cause of death code
T40.0-T40.4, T40.6

Abbreviations: ICD-9, International Classification of Diseases, Ninth Revision; ICD-10,
International Classification of Diseases, Tenth Revision; EHR, electronic health record
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APPENDIX B
Variables of interest among veterans with an opioid overdose
Characteristic

Variable

Related ICD codes

Sex

Sex (1=male, 0=female)

Used last entered value

Age

Age (Continuous)

Age as of January 1, 2011

Date of visit

V_date (in SAS date9.
format)

Time period 01/01/2011-12/31/2015

Psychosocial & related mental health diagnoses
ICD-9: 290.00 to 319.99, excluding tobacco codes starting with
305
ICD-10: F00 to F99, excluding tobacco codes starting with F17
ICD-9: 300
ICD-10: F40, F41

Any mental health
diagnosis

mh_dx (1=yes, 0=no)

Anxiety

anx_dx (1=yes, 0=no)

Depression

dep_dx (1=yes, 0=no)

ICD-9: 296.2, 296.3, 300.4, 311
ICD-10: F32, F33, F34.1

Bipolar

bip_dx (1=yes, 0=no)

ICD-9: 296.0, 296.1, 296.4, 296.5, 296.6, 296.7, 296.8
ICD-10: F31

PTSD

ptsd (1=yes, 0=no)

ICD-9: 309.81
ICD-10: F43.1

Adjustment disorder

adj_dx (1=yes, 0=no)

Schizophrenia or other
psychotic disorders

sch_dx (1=yes, 0=no)

Traumatic stress

trst_dx (1=yes, 0=no)

Personality disorder

per_dx (1=yes, 0=no)

Opioid
abuse/dependence
Alcohol
abuse/dependence

op_dx (1=yes, 0=no)
alc_dx (1=yes, 0=no)

Cannabis
abuse/dependence

can_dx (1=yes, 0=no)

Sedative, hypnotics, or
anxiolytic
abuse/dependence
Cocaine
abuse/dependence

sha_dx (1=yes, 0=no)

Other stimulant
abuse/dependence

stm_dx (1=yes, 0=no)

coc_dx (1=yes, 0=no)

ICD-9: 309.0, 309.24, 309.28, 309.3, 309.4, 309.9
ICD-10: F43.20- F43.25
ICD-9: 295.90, 295.40, 295.70, 297.1, 297.3, 298.8, 293.81,
293.82, 298.9
ICD-10: F20.9, F20.81, F25.0, F25.1, F22, F24, F23, F06.2,
F06.0, F29)
ICD-9: 308.9, 309.89, 309.9
ICD-10: F43.0 F43.8, F43.9
ICD-9: 301.83, 301.7, 301.81, 301.50, 301.4, 301.82, 301.6,
301.0, 301.20, 310.1 301.9
ICD-10: F60, F61
ICD-9 codes: 304.0, 304.7, 305.5
ICD-10 codes: F11
ICD-9: 303, 305.0
ICD-10: F10
ICD-9: 304.3, 305.2
ICD-10: F12
ICD-9: 304.1, 305.4
ICD-10: F13
ICD-9: 304.2, 305.6
ICD-10: F14
ICD-9: 304.4, 305.7
ICD-10: F15
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Hallucinogen
abuse/dependence

hal_dx (1=yes, 0=no)

Any substance
abuse/dependence

anysub_dx (1=yes,
0=no)

Polysubstance
abuse/dependence

polysub_dx (1=yes,
0=no)

More than 1 diagnosis for substance abuse/dependence

tbi_dx (1=yes, 0=no)

ICD-9: 800.0-801.9, 803.0-804.9, 850.0-854.1, 950.1-950.3,
995.55, 959.01
ICD-10: S02.0, S02.1, S02.8, S02.91, S04.02, S04.03, S04.04,
S06, S07.1, T74.4

TBI

ICD-9: 304.5, 305.3
ICD-10: F16
Any diagnosis for substance abuse/dependence

Medication-Assisted Treatment (MAT)
Record of MAT

MAT

Using stop code 523 (primary or secondary stop code) to identify
MAT services

Chronic pain before index OD
ICD-9: 720.0-724.9
ICD-10: M45.9- M46.1, M46.90, M47.812, M47.12, M47.814,
M47.817, M48.20, M48.10, M48.30, M48.9, M50.20, M51.9,
M50.30, M51.34-M51.37, M48.02, M54.2, M53.0, M53.1,
M54.12, M54.13,M43.6, M54.02, M67.88, M53.82, M54.6,
M54.5, M54.30, M54.14-M54.17, M54.89-M54.9, M43.27,
M43.28, M53.2X7, M53.3, M54.08, M43.8X9, M53.9
ICD-9: 710.0-739.9, excluding back pain codes
ICD-10: M00-M02, M36.2, M36.3, M12, M35.3, M15, M16M19, M05-M08, M1A, M10-M14
ICD-9: 346.0-346.9
ICD-10:G43.0, G43.1, G43.4, G43.5, G43.6, G43.7, G43.8,
G43.9, G43.A, G43.B, G43.C, G43.D
ICD-9: 784.0 and 307.81
ICD-10: G44.1, R51, G44.209

Back pain

b_pain (1=yes, 0=no)

Arthritis

a_pain (1=yes, 0=no)

Migraines

m_pain (1=yes, 0=no)

Headaches or tension
headaches

h_pain (1=yes, 0=no)

Psychogenic

p_pain (1=yes, 0=no)

ICD-9: 307.80 and 307.89
ICD-10: F45.41, F45.42

Neuropathy

n_pain (1=yes, 0=no)

Fibromyalgia

f_pain (1=yes, 0=no)

ICD-9: 355.0, 355.9, 356.0, 357.2, 357.9
ICD-10:G57.00, G58.9, G60, E08.42, E09.42, E10.42, E11.42,
E13.42, G61.9
ICD-9: 729.1
ICD-10: M60.9, M79.1, M79.7

Any chronic pain
diagnosis

chr_dx (1=yes, 0=no)

Any of the diagnoses for chronic pain

Social determinants of health (SDoH) codes prior to index OD
Problems related to
housing and economic
circumstances
Problems related to
support group,
including family and
relationships
Problems related to
social environment

Prob_econ
(1=yes, 0=no)

ICD-9: V60.0, V60.1, V60.89, V60.6, V60.2, V60.9
ICD-10: Z59 (Z59.0-Z59.9)

Prob_supp
(1=yes, 0=no)

ICD-9: V61.0, V61.05, V61.8, V61.01, V61.06, V61.07,
V61.08, V62.82, V61.03, V61.49, V61.02, V61.41, V61.3,
V61.04, V61.09, V61.8, V61.9
ICD-10: Z63 (Z63.0-Z63.9)
ICD-9: V60.3, V62.4, V62.89
ICD-10: Z60.0, Z60.2, Z60.3, Z60.4, Z60.5, Z60.8, Z60.9

Prob_soenv
(1=yes, 0=no)
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Problems related to
upbringing

Prob_upbr
(1=yes, 0=no)

ICD-9: V61.29, V61.8, V60.81
ICD-10: Z62.0, Z62.1, Z62.2, Z62.3, Z62.6, Z62.8

Problems related to
environmental
psychosocial
circumstances
Problems related to
abuse

Prob_enpsych
(1=yes, 0=no)

ICD-9: V62.5, V62.89, V62.81, V62.9
ICD-10: Z65.0, Z65.1, Z65.2, Z65.3, Z65.4, Z65.5, Z65.8, Z65.9

Prob_abuse
(1=yes, 0=no)

ICD-9: V61.21, V61.22, V62.83, V61.11, V61.12, V65.49
ICD-10: Z69.0, Z69.01, Z69.02, Z69.1, Z69.8

Counseling services

Prob_coun
(1=yes, 0=no)

ICD-9: V65.49, V61.2, V61.1, V65.40, V65.9
ICD-10: Z71.81, Z71.89, Z71.9

Other problems related
to mental and behavior

Prob_menbeh
(1=yes, 0=no)

ICD-9: V40.0, V40.2, V40.3, V40.31, V40.39, V40.9
ICD-10: F48.9, F69

Any SDoH

any_sdoh
(1=yes, 0=no)

Any of the above SDoH codes captured before index OD

Abbreviations: ICD, International Classification of Disease; ICD-9, International Classification of Disease, Ninth
Edition; ICD-10, International Classification of Disease, Tenth Edition; PTSD, Post-traumatic stress disorder; TBI,
Traumatic Brian Injury; MAT, Medication-Assisted Treatment; OD, overdose; SDoH, social determinant of health
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APPENDIX C
Diagnostic codes used to classify indicators of social determinants of health
Description
Problems related to housing
and economic circumstances

Description
•
•
•
•
•
•
•
•
•
•

Problems related to support
group, including family and
relationships

•
•
•
•
•
•
•
•
•

Problems related to social
environment

•
•
•
•
•
•
•

ICD code

Homelessness
Inadequate housing
Discord with neighbors, lodgers and
landlord
Problems related to living in residential
institution
Lack of adequate food and safe drinking
water
Extreme poverty
Low income
Insufficient social insurance and welfare
support
Other problems related to housing and
economic circumstances
Problem related to housing and economic
circumstances, unspecified

ICD-9: V60.0, V60.1, V60.89,
V60.6, V60.2, V60.9

Problems in relationship with spouse or
partner
Problems in relationship with in-laws
Absence of family member
Disappearance and death of family member
Disruption of family by separation and
divorce
Dependent relative needing care at home
Other stressful life events affecting family
and household
Other specified problems related to primary
support group
Problems related to primary support group,
unspecified

ICD-9: V61.0, V61.05, V61.8,
V61.01, V61.06, V61.07, V61.08,
V62.82, V61.03, V61.49, V61.02,
V61.41, V61.3, V61.04, V61.09,
V61.8, V61.9

Problems of adjustment to life-cycle
transitions
Problems related to living alone
Acculturation difficulty
Social exclusion and rejection
Target of (perceived) adverse
discrimination and persecution
Other problems related to social
environment
Problem related to social environment,
unspecified

ICD-9: V60.3, V62.4, V62.89

ICD-10: Z59 (Z59.0-Z59.9)

ICD-10: Z63 (Z63.0-Z63.9)

ICD-10: Z60.0, Z60.2, Z60.3,
Z60.4, Z60.5, Z60.8, Z60.9
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Problems related to
upbringing

•
•
•
•
•
•

Inadequate parental supervision and control
Parental overprotection
Upbringing away from parents
Hostility towards and scapegoating of child
Inappropriate (excessive) parental pressure
Other specified problems related to
upbringing

Problems related to
environmental psychosocial
circumstances

•

Conviction in civil and criminal
proceedings without imprisonment
Imprisonment and other incarceration
Problems related to release from prison
Problems related to other legal
circumstances
Victim of crime and terrorism
Exposure to disaster, war and other
hostilities
Other specified problems related to
psychosocial circumstances
Problem related to unspecified psychosocial
circumstances

•
•
•
•
•
•
•

Problems related to abuse

•
•
•
•
•

Counseling services

Other problems related to
mental and behavior

Any SDoH

Encounter for mental health services for
child abuse problems
Encounter for mental health services for
parental child abuse
Encounter for mental health services for
non-parental child abuse
Encounter for mental health services for
spousal or partner abuse problems
Encounter for mental health services for
victim or perpetrator of other abuse

ICD-9: V61.29, V61.8, V60.81
ICD-10: Z62.0, Z62.1, Z62.2,
Z62.3, Z62.6, Z62.8

ICD-9: V62.5, V62.89, V62.81,
V62.9
ICD-10: Z65.0, Z65.1, Z65.2,
Z65.3, Z65.4, Z65.5, Z65.8, Z65.9

ICD-9: V61.21, V61.22, V62.83,
V61.11, V61.12, V65.49
ICD-10: Z69.0, Z69.01, Z69.02,
Z69.1, Z69.8

•
•
•

Spiritual or religious counseling
Other specified counseling
Counseling, unspecified

ICD-9: V65.49, V61.2, V61.1,
V65.40, V65.9

•
•

Nonpsychotic mental disorder, unspecified
Unspecified disorder of adult personality
and behavior

ICD-9: V40.0, V40.2, V40.3,
V40.31, V40.39, V40.9

ICD-10: Z71.81, Z71.89, Z71.9

ICD-10: F48.9, F69

Any of the above SDoH codes captured before index OD

Abbreviations: ICD, International Classification of Disease; ICD-9, International Classification of Disease, Ninth
Edition; ICD-10, International Classification of Disease, Tenth Edition; SDoH, social determinant of health
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APPENDIX D
Underlying cause of death codes used for cause-specific mortality
Cause of death

ICD-10 Codes Associated With Underlying Cause of Death

Opioid overdose

X40-X44, X60-X64, X85, Y10-Y14 with secondary axis codes T40.0-T40.4, T40.6

External Cause of death

X60-X84, Y87.0, X85-Y09, Y87.1, V01-X39, X46-X59, Y85-Y86

Suicide

X60-X84, Y87.0

Homicide

X85-Y09, Y87.1

Accidents

V01-X39, X46-X59, Y85-Y86

Substance-related

Drug-related

Alcohol-related
Infectious

F11.0-F11.5, F11.7-F11.9, F12.0-F12.5, F12.7-F12.9, F13.0-F13.5, F13.7-F13.9,
F14.0-F14.4, F14.7-F14.9, F15.0-F15.5, F15.7-F15.9, F16.0-F16.5, F16.7-F16.9,
F17.0, F17.3-F17.5, F17.7-F17.9, F18.0-F18.5, F18.7-F18.9, F19.0-F19.5, F19.7F19.9, X40–X44, Y10–Y14, F10, G31.2, G62.1, I42.6, K29.2, K70, R78.0, X45,
Y15
F11.0-F11.5, F11.7-F11.9, F12.0-F12.5, F12.7-F12.9, F13.0-F13.5, F13.7-F13.9,
F14.0-F14.4, F14.7-F14.9, F15.0-F15.5, F15.7-F15.9, F16.0-F16.5, F16.7-F16.9,
F17.0, F17.3-F17.5, F17.7-F17.9, F18.0-F18.5, F18.7-F18.9, F19.0-F19.5, F19.7F19.9, X40–X44, Y10–Y14
F10, G31.2, G62.1, I42.6, K29.2, K70, R78.0, X45, Y15
A00-B99

Viral hepatitis
HIV

B15-B19
B20-B24

Circulatory system

I00-I99

Respiratory system

J00-J98

Influenza & pneumonia

J09-J18

Chronic respiratory
disease
Digestive system

J40-J47

Cirrhosis & alcoholic
liver disease
Cancer

K70, K73-74

K00-K92

C00-D48

Lung & bronchus

C34

Liver & intrahepatic bile
duct
Digestive system

C22

Lymphoma & leukemia
Other cancers

C15-C21, C23-C26
C82-C85, C91-C95
C00-C14, C27-C33, C35-C81, C86-C90, C96-D48

Abbreviations: ICD-10, International Classification of Diseases, Tenth Edition; HIV, human immunodeficiency
virus
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